Categories and read-across are essential tools for supplying information for assessments of endpoints without data while minimizing animal testing. This study is based on the guidance of ECHA in its Read-Across Framework (RAAF). A category of C1 -C8 alkyl methacrylate esters (methyl, ethyl, n-butyl, iso-butyl and 2-ethylhexyl) was constructed to fill in missing information for human health endpoints using read-across as a permitted adaptation under EU REACH. The esters form a series with common functional groups, small incremental changes of electrophilicity by molecular weight, and rapid hydrolysis by ester cleavage. Read-across is justified by two common specific modes of action, direct electrophilic reaction of the parent compounds and the potential inherent toxicities of the common metabolites methacrylic acid and the corresponding alcohols. The toxicological profile is very similar for all category members and not driven by the alcohol metabolites. Data gaps can be filled in with high confidence based on the number of studies available, the effects therein observed and the toxicological profiles of the hydrolysis products. The guidance provided by the RAAF enabled data gaps to be filled in a robust manner.
Introduction
The EU REACH regulation (EC, 2006 ) set a new precedent for requiring comprehensive data sets of high quality human health and the environment data that due to international trade impacts chemical industry around the world. Under animal welfare considerations, the same regulation called for the use of non-animal testing as far as possible (cf. article 13 and 47 of EC, 2006) . Use of such alternative approaches, however, raises questions over what are acceptable levels of sensitivity and specificity for different regulatory purposes i.e. prioritization, classification and labeling or risk assessment. One way of utilizing high quality, existing animal data but still avoiding further animal tests is to use read-across, whereby information from a similar source chemical(s) is used to predict the same endpoint for a target substance. Read-across is a well-established basis of informed toxicological viewpoints for many years. While internationally agreed performance standards have been elaborated for QSAR and in vitro approaches, international frameworks are missing for read-across. With the increased focus on the use of read-across and the need for transparency and standardization an increasing number of publications and guidance document have been published, e.g. ECETOC (2012) , OECD (2014), Patlewicz et al. (2013 Patlewicz et al. ( , 2014 , Schultz et al. (2015) and Berggren et al. (2015) . In 2015 ECHA issued a Read-Across Assessment Framework (RAAF) for human health endpoints (ECHA, 2015) that was subsequently extended to include environmental endpoints (ECHA, 2017a) .
In the present communication ECHA's RAAF guidance has been applied to the relatively straight forward category of lower alkyl methacrylate esters that contain short-chain C1-C8 alkyl esters of methacrylic acid (MAA), namely methyl methacrylate (MMA), ethyl methacrylate (EMA), n-butyl methacrylate (n-BMA), iso-butyl methacrylate (i-BMA) and 2-ethylhexyl methacrylate (2-EHMA). Structures are given in Fig. 1 . These substances are important monomers with production volumes of greater than 1000 tons per year and potential for widespread exposure. 2-EHMA was selected as upper boundary of this category for practical reasons, i.e. inhalation exposure to vapors of methacrylate esters is of highest concern at the workplace that prevails for the lower molecular weight members of this group.
With increasing molecular weight there is a potential shift to aerosol exposure due to increasing boiling points that becomes rather unlikely under conditions of normal use. Vapor and aerosol exposures require different considerations for inhalation toxicity. Therefore, higher esters are excluded here but may subsequently be considered as a separate category.
While most of the available guidances stop short of giving examples or case studies for read-across, ECETOC (2012) does and includes a short version of a category approach for the same group of the lower alkyl methacrylate esters that is further elaborated here. This category has also been assessed in the SIDS Initial Assessment Report for SIAM 18 of OECD (2004a) . In addition, the TSCA New Chemicals Program contains a category for "acrylates/methacrylates" without giving any details for its scientific justification (US EPA, 2010) . The present assessment takes into account the guidance of OECD (2014) as well as the RAAF of ECHA (2015, 2017a) to strengthen the category approach first submitted in 2010 under EU REACH. In the present publication we show how read-across can be used to establish NOAELs after oral and inhalation exposure, a necessary requirement for risk assessments. Consequences for classification and labelling according to the REACH regulations are not discussed.
This paper is based upon data in the IUCLID data sets for each category member, MAA and the respective alcohols that are publicly available on the ECHA (2017b) websites and supplemented by a literature search conducted in January 2017 in case more recent information had become available. The search strategy was based on the STN databases, starting from the CAS numbers (including the different salts of MAA) and interrogated for the different toxicological endpoints including metabolism and toxicokinetics. This paper proposes a category approach for the toxicological assessment of short chain methacrylate esters to fill in data gaps by readacross. Estimates for repeated dose toxicity are derived for the group members with no experimental data to satisfy information requirements of the EU REACH regulation. The scenarios described by ECHA (2015 ECHA ( , 2017a have been used to describe the mechanisms relevant for the different endpoints. The scheme proposed by Blackburn and Stuard (2014) is applied to define the level of uncertainty of each read-across (cf. electronic supplement).
2. Read-across assessment according to the framework (RAAF) of ECHA (2015 ECHA ( , 2017a 
Preparatory assessment and substance identities
The RAAF requires a preparatory assessment before the read-across can be conducted. A fundamental aspect of read-across is structural similarity. The chemical composition of the members must be well defined and include information on other constituents (e.g. impurities) that can have a significant impact on the hazard or fate of a substance (ECHA, 2015 (ECHA, , 2017a .
Commercial grades of these substances are of high purity (> 98%). All are stabilized against spontaneous polymerization by low levels of quinone-based stabilizer, e.g., hydroquinone or hydroquinone monomethyl ether. Impurities include predominantly water and the corresponding alcohols used in their manufacture. The profiles of other trace impurities are very similar and of minor importance since their levels are not anticipated to influence the toxicological profile.
The boundary (applicability domain) of this category is defined by the chain length of the alcohol moiety starting from C1 (MMA) to C8 (2-EHMA) for group members. The alcohol moieties are either linear (EMA, n-BMA) or branched (i-BMA, 2-EHMA). An overarching source chemical for all endpoints is MMA with a complete data set. 2-EHMA was selected as upper boundary since esters larger than 2-EHMA can be distinguished by appreciable differences in vapor pressure, water solubility and n-octanol/water partition coefficient. For example, for dodecyl methacrylate (DDMA) the vapor pressure is 0.006 (hPa at 20°C), the water solubility < 0.001 (mg/l at 20°C) and the partition coefficient n-octanol/water 6.68 (log value). These properties clearly distinguish DDMA and higher esters from 2-EHMA (cf. Table 1 ).
There is a clear trend in physico-chemical properties by chain length of the alcohol group across the category (ECETOC, 2012) ( Table 1) . As a rule, boiling point and octanol/water partition coefficient increase and vapor pressure and water solubility decrease with increasing molecular weight/volume. With the increase of the octanol/water partition coefficient with molecular weight, dermal penetration decreases as has been shown by Jones (2002) . The decreasing vapor pressure with molecular weight at ambient temperature cautions that adverse effects occurring at higher concentrations may be due to aerosol formation. This was the main reason to select 2-EHMA as the upper bound of this category. As the toxicological database is different for each endpoint, the available data on the category members are listed separately under the endpoints H.-P. Gelbke et al. Regulatory Toxicology and Pharmacology 92 (2018) showing whether, and to what extent, trends and similarities exist.
Description and assignment of the RAAF scenarios
The RAAF guidance (ECHA, 2015 (ECHA, , 2017a ) defines 6 different scenarios for read-across. A tiered approach to selection of the most appropriate scenario is recommended: first select between analogue and category approaches. The present study is a category approach which eliminates the analogue scenarios (1 and 2). Within the category approach ECHA foresees two options namely a) (bio)transformation to common compound(s) (scenarios 3 and 5) and b) different compounds having the same type of effect(s) (scenarios 4 and 6). In this case the different methacrylate esters are metabolized to the common MAA metabolite but different alcohols. As long as the different alcohols do not impact toxicity (as will be investigated for the different endpoints) the first hypothesis (Scenario 3) would apply. Scenarios 4 is assigned when there is a regular pattern of effect. Scenarios 5 and 6 are modifications of scenarios 3 and 4, respectively, in case there is no variation among the category members. Key to assigning the most appropriate scenario is to understand how different scenarios may apply to different endpoints.
Scenario 3 and 5: read-across based on biotransformation to a common compound
The read-across for systemic toxicity of the lower methacrylate esters is based primarily on the rapid hydrolysis of the esters to MAA and the corresponding alcohol (cf. Fig. 1 ). The impact of the length of the alcohol group on hydrolysis is unclear: higher molecular weight alcohols may be better leaving groups but the bulkier ester may have less access to the active center of the carboxylesterase. Systematic studies in this respect were not available to the authors. All short chain methacrylate esters are hydrolyzed by carboxylesterases that are widely distributed throughout the body and have a high activity within many tissues, including the liver, blood, gastro-intestinal tract, nasal epithelium and skin (Satoh and Hosokawa, 1998; Junge and Krisch, 1975; Bogdanffy et al., 1987; Frederick et al., 1994) . Rapid hydrolysis has been confirmed for the olfactory and nasal respiratory tract, the blood, skin and liver of rats and humans (Jones, 2002) . Based on data for partition coefficients and rate of hydrolysis in blood and liver of rats and humans, a PBPK model was developed by Jones (2002) . As shown in Table 2 (adapted from Jones, 2002 ) the systemically available ester is eliminated from the body with short initial half-lives (T50%) increasing with increasing chain length from 4.4 min for MMA to 23.8 min for 2-EHMA with more than 99% being cleared by the first pass through the liver (%LBF). Of the two metabolic products, MAA enters a rapid physiologic degradation pathway again with a very short half-life of < 5 min. MAA is cleared predominantly via the liver forming carbon dioxide and water (Bratt and Hathway, 1977) . The different alcohols after ester cleavage are generally of low toxicity and their potential impact on systemic toxicity will be counterchecked for repeated dose and fertility/developmental effects. Thus in general, ester cleavage can be considered a detoxification pathway for systemic effects.
For local toxicity, especially after inhalation, a different situation exists. Here intracellular ester cleavage may lead to cytotoxicity by MAA induced decrease of pH. The molecular initiating event (MIE) is decreased intracellular pH and the adverse outcome pathway (AOP) is ester cleavage. The alcohol moieties can be considered as locally nontoxic metabolites within the relevant dose ranges.
For a category approach based on metabolism/toxicokinetics ECETOC (2012) and OECD (2014) have defined some important criteria that are well fulfilled by the category of the lower methacrylate esters:
-The metabolic pathway must be consistent between experimental animals and humans (ECETOC) -addressed above. -The metabolism must be rapid and complete so that the metabolite will be the chemical entity predominantly found in blood (ECETOC) -addressed above. -Ideally the metabolism (break down) of the parent chemical should occur rapidly in barrier tissues like skin, gastro-intestinal or respiratory tract (OECD, ECETOC), but liver (after oral exposure) or placenta may also represent such a barrier for systemic effects or Table 2 PBPK model for clearance of MAA and methacrylates with increasing chain length by first pass liver metabolism and elimination from the body following i.v. administration to rats (Jones, 2002 H.-P. Gelbke et al. Regulatory Toxicology and Pharmacology 92 (2018) 104-127 those potentially affecting the embryo (ECETOC) -to be addressed in the sections for dermal and inhalation exposure. -For effects at the site of contact, it must be differentiated whether they are exerted primarily by the parent chemical or by the metabolite (OECD) -to be addressed for inhalation exposure.
Some examples of categories defined by ester hydrolysis are briefly discussed by ECETOC (2012), namely propylene glycol ether and its acetate, esters of propionic acid and the case study of Cycla-esters. Ester cleavage leading to a common break-down product has already been successfully applied in the OECD HPV SIDS program for an analogue assessment for isobutyl isobutyrate in analogy to isobutanol and isobutyric acid (OECD, 2005) , for 2-ethylhexyl acetate in analogy to 2-ethylhexanol and acetic acid (OECD, 2010) and for methyl formate in analogy to methanol and formic acid (OECD, 2008) . ECHA (2013) has published an illustrative example for a hypothetical read-across between two structurally related esters (analogue approach) based on the similarities of the break down products. Here ester hydrolysis was assumed to take place directly by contact with water (http://echa.europa. eu/documents/10162/13628/read_across_example_1_en.pdf).
2.4. Scenario 4 and 6: read-across based on the same type of effect These scenarios are governed by the electrophilicity of the intact ester.
The ester group is common to all members of the group. Ester hydrolysis by ubiquitous carboxylesterases already occurs at the portal of entry to a degree depending on molecular weight and is nearly complete after first pass liver metabolism. However, especially after inhalation or at high exposure levels, residual intact ester may reach systemic circulation and exert an influence on systemic toxicity through macromolecular binding. Such effects are considered to vary slightly and monotonically within the category. As some influence of the intact ester cannot be excluded, scenarios 4 may apply to a minor extent. On the other hand, especially for sensitization and (in vitro) genotoxicity, these scenarios may be more relevant.
The methacrylate esters contain an α,β unsaturated carbonyl group. Electrophilicity of methacrylate esters as MIE may result in electrophilic reactions of the intact ester with DNA or proteins (AOP). Nucleophilic attack at the ß-C-atom, and to a lesser extent the carbonyl C-atom, is referred to as Michael addition (cf. Fig. 1 ). Michael-receptor reactivity of the intact esters is determined to a major extent by the structure of the acyl subgroup. In contrast to acrylate esters, the α-methyl substitution decreases the electrophilicity by a +I-effect and impairs electrophilic reaction by steric hindrance. Therefore, methacrylate esters show a low electrophilic reactivity, e.g. for conjugation with GSH (McCarthy and Witz., 1991; McCarthy et al., 1994; Tanii and Hashimoto, 1982) , so GSH conjugation and/or addition to nucleophiles possibly may only play a role at very high tissue concentrations, when metabolism by carboxylesterases becomes saturated.
A minor impact is also exerted by the +I-effect of the alcohol subgroup, but the incremental impact on electrophilicity rapidly decreases with increasing alcohol chain length. Therefore for direct electrophilic reactions the alcohol group will only have a minor, rather monotonic influence with increasing chain length. Chan and O'Brien (2008) showed that toxicity against rat hepatocytes and glutathione (GSH) reactivity could be closely modelled by the electronic parameters E LUMO and partial charge of the reactive carbon atoms. Methacrylate esters including MMA, EMA and i-BMA exhibited a much lower in vitro cytotoxicity and GSH reactivity in comparison to acrylates. The differences within the group of methacrylate esters were much smaller than those between both groups. While GSH reactivity slightly decreased in the order MMA > EMA > i-BMA, a reversed order was observed for cytotoxicity. This may indicate that other factors besides GSH reactivity may be determinants for the slight differences measured for in vitro cytotoxicity of methacrylate esters. Böhme et al. (2009) developed a kinetic GSH chemo-assay to measure electrophilic reactivity of 26 α,β-unsaturated carbonyl compounds in the context of structure-activity relationship. The GSH reactivity of MMA and EMA was at the lowest end of all substances tested. The low Michael-receptor reactivity of MMA and EMA within a series of 47 α,β-unsaturated carbonyl compounds has been shown by quantum chemical transition state calculation that enabled to predict growth inhibition (EC 50 ) of the ciliate Tetrahymena pyriformis. Interestingly, the predicted EC 50 of EMA was slightly higher than that of MMA (Mulliner et al., 2011) . Substances studied by Böhme et al. (2009) and Mulliner et al. (2011) included for example acrylates, α,β unsaturated aldehydes and ketones. Similar findings were reported by Fujisawa and Kadoma (2012) . They correlated GSH reactivity (as potential indicator for biological activity) with 13 C NMR chemicals shifts for several acrylates and methacrylate esters and observed that GSH reactivity depends on the π-electron density at the ß-C-atom. For the methacrylate esters included, GSH reactivity slightly decreased from MMA to EMA and n-BMA, corresponding to the increased + I effect of the alcohol moiety, and was the same for EMA and i-BMA. The reactivity of acrylates always was clearly higher than that of the methacrylic acid esters.
Assessment elements (AEs)
For category approaches ECHA (2015, 2017a) defines AEs which represent crucial scientific aspects that have to be satisfied before the read-across can be considered. These are either common to all category scenarios (AE C) or specific to scenarios 3 and 5 (AE 3, AE 5) or 4 and 6 (AE 4, AE 6), respectively. As the AEs vary from scenario to scenario it is critical that the most appropriate read across scenario is selected for each endpoint. Common and specific AEs together with their levels of confidence are presented for the group members in Table 3 .
General considerations for AOPs/MIEs of different toxicological endpoints
Based on the chemical reactivity of the intact esters and their metabolic fate there are 2 principles that may govern the different toxicological endpoints: a. Direct electrophilic reactions of the intact ester, corresponding to scenario 4/6 and governed by AE 2 and 3 (common underlying mechanism, qualitative and quantitative aspects). Such a mechanism may be most relevant for mutagenicity/genotoxicity or for sensitization. In principle, it may also play a role for local toxicity by electrophilic binding to macromolecules in cells at the portal of entry. But because of rapid local hydrolysis to MAA with decreased intracellular pH, scenario 3/5 will dominate and a quantitative differentiation between scenario 3/5 and 4/6 is not possible. In addition, a minor contribution due to rapid ester hydrolysis cannot be excluded for systemic toxicity at high doses or after inhalation when first pass liver metabolism becomes incomplete. Again, scenario 3/5 will be most relevant and an estimate about the relative contribution in relation to scenario 4/6 at high doses is not possible. b. Local effects after ester cleavage leading to high intracellular cytotoxic concentrations of MAA, corresponding to scenario 3/5 and governed by AE 2 and 3 (biological target and its exposure to the common compound). This may in principle play a role for every exposure route depending on the exposure concentration, the rate of passage through, and the rate of metabolism within the local tissues. This scenario is most relevant for local effects on the nasal passages after inhalation and a robust database is available in this regard. Severe effects after dermal or oral exposure that may be related to local formation of MAA have not been observed.
Systemic effects after entry into systemic circulation will predominantly be determined by scenario 3/5 governed with AE 2 and 5 (target for common compound and impact of non-common compounds). Due to the rapid ester cleavage the contribution by parent ester will be minimal and this scenario will be governed by MAA, the metabolite common to all members of this group, and the corresponding alcohol. As the common compound is rapidly detoxified by physiological metabolic pathways, specific systemic effects are not to be assumed and have not been identified. The potential impact of the noncommon compounds (alcohols) is investigated in detail for the different endpoints. This mechanism will be pivotal for repeated dose toxicity and reproductive effects.
General considerations for levels of uncertainty
Blackburn and Stuard (2014) describe a system how to assess levels of uncertainty in the read-across approach for repeated dose and developmental/reproductive toxicity based on the number of analogue data and their robustness, the concordance of effects and potency and severity of effects. In contrast to the acceptability scheme of ECHA (2015, 2017a) this system gives guidance for the most important considerations defining uncertainty and therefore will be used here for the respective endpoints. Details are given in the electronic supplement. Some more general aspects of level of confidence are described in several of the above mentioned read-across publications. Even for a well-founded scientific similarity rationale it is intuitive that:
1. Extrapolation may be associated with less confidence than interpolation; this may become relevant for the member at the upper end of the category, i.e. 2-EHMA; 2. One-to-one read-across (although this is the basis for an analogue approach) may be associated with less confidence than many-to-one read-across, and 3. It is more critical to conclude an absence of effects than to readacross for effects showing a regular pattern within the category.
Some considerations for the level of confidence that may be common to the category under consideration are already mentioned here. Firstly, the methacrylate esters contain branched and unbranched alcohols that may impact ester hydrolysis. This is addressed in Table 2 showing that the initial half-lives (T50%) of i-BMA and n-BMA as well as those of hexyl methacrylate, octyl methacrylate and 2-EHMA are comparable and short. In addition, the first pass liver clearance is > 99% for branched as well as linear esters. Collectively this indicates that the influence of branched vs. unbranched alcohols on ester hydrolysis is small. Secondly, ester cleavage leads to MAA and different alcohols. Therefore, the NOAELs obtained for the esters by read-across will be validated by the NOAELs of the respective alcohols. Thirdly, the potential impact of residual intact ester has to be considered especially after inhalation exposure when first pass liver metabolism is partially bypassed and when relatively high NOAELs are extrapolated for repeated dose and reproductive/developmental toxicity. In this respect the similar electrophilicity of all esters have to be taken into consideration.
The levels of uncertainty may also be considered separately for both AOPs. As regards the AOP of direct electrophilic reactions of the intact esters leading to macromolecular binding as MIE, electrophilicity of all members is very similar and only a slight decrease with molecular Due to rapid ester hydrolysis in vivo (cf. scenarios 3 and 5) potential toxicity of the intact esters will only play a minor role; potential impact of alcohols will be ascertained H.-P. Gelbke et al. Regulatory Toxicology and Pharmacology 92 (2018) 104-127 weight can be distinguished. Thus its impact on inter-or extrapolated NOAELs can only be small leading to low uncertainty. The second AOP is ester cleavage leading to MAA and the respective alcohols. MAA once formed is rapidly metabolized, but its intracellular formation may lead to a decrease of local pH as MIE accompanied by cytotoxicity. This pathway is of major importance and relatively unique for local effects in the olfactory epithelium after inhalation. A strong data set has shown how this effect decreases with increasing molecular weight of the esters. A different situation exists once the ester has entered systemic circulation. Ester cleavage is more widespread and not tissue specific. Due to the rapid metabolism by a physiologic pathway, systemic MAA is rapidly cleared and is not expected to exert specific systemic adverse effects. Thus, the uncertainty for data fill-in based on systemic formation of MAA is low. The toxicity of the alcohols formed as the other component of this pathway has been evaluated for the different repeated dose endpoints. It could be demonstrated that the effects of methacrylate esters are not driven by their alcohol components that therefore will not impact the level of uncertainty. Thus, also for the AOP of ester cleavage the uncertainties will generally be low for systemic and local effects.
Although these general considerations indicate low uncertainties for both AOPs, their relative prevalence depending on distribution of enzyme activity, exposure route and level deserves to be addressed. By PBPK modelling Jones (2002) showed that the half-lives of the esters are relatively short and increase with molecular weight from 4.4 min (MMA) to 23.8 min (2-EHMA) across the category. This increase is in part due to intermediary storage in fat tissues, an effect that increases with increasing molecular weight. Also, half-life determinations were based on single intravenous bolus application of 10 mg/kg which is much lower than the repeated dose NOAELs described below. This data shows that systemically available intact ester will increase with molecular weight and that possibly at higher dose levels larger amounts of intact ester may escape from first pass liver metabolism. In addition, after inhalation part of the intact ester that is not hydrolyzed in the upper respiratory tract will bypass the liver. Carboxylesterases are present in all tissues, including the blood, further hydrolyzing the residual intact esters, albeit to a quantitatively unknown extent. But as electrophilicity is very similar over the whole group, the level of uncertainty will not be impacted to any appreciable extent by such residual esters.
ECHA (2015, 2017a) defines levels of acceptability for read-across (acceptable with high, medium or just sufficient confidence; not acceptable in its present form or not acceptable). However, as detailed criteria for their assignment is lacking in the guidance we chose to translate these to the levels of uncertainty as defined by Blackburn and Stuard (2014) (cf. Table 11 ). When common and specific AEs in Table 3 are evaluated according to the ECHA criteria for acceptability a generally high level of confidence applies for all AEs. More details using the system of Blackburn and Stuard (2014) are given under the specific endpoints, including the few exceptions (respiratory sensitization, acute and developmental toxicity of 2-EHMA by inhalation).
Category justification and results of read-across by endpoint
For some endpoints there are data for all members of the category in which case read-across is not required. Most importantly, for these endpoints the available data do not contra indicate the use of the category approach for other endpoints where read-across is employed.
Acute toxicity and irritation
Acute systemic effects will mainly depend on the systemic availability of MAA and the alcohols (scenarios 3 and 5 of ECHA, 2015 ECHA, , 2017a , but due to the high doses applied a part of the esters may escape from first pass liver detoxification. The intact ester may then react with macromolecules by electrophilic interaction. This corresponds to scenarios 4 and 6. Thus, there is a mix of scenarios 3 and 5 on the one hand and 4 and 6 on the other, but the former will prevail because of the of the short initial half-lives of the intact esters between 4.4 and 23.8 min. Local effects may be caused by either intracellular concentration of MAA (scenario 3 and 5) or toxicity caused by direct electrophilic reactions (scenario 4 and 6). As the aim for acute toxicity testing is primarily the identification of the range of lethality by the time of necropsy, 14 days after application, any reversible effects, like local irritation, would not persist to the end of the observation period. There are data for members of the category to estimate acute toxicity by the three exposure routes. While some of the studies do not include all elements of modern guidelines, taken as a whole the information is sufficient to enable an assessment and to demonstrate the interrelationship of ester cleavage, irritancy and toxicity.
Acute oral toxicity
Adequate data are available for all members of the category so readacross is not required. LD 50 values are generally either slightly above 9000 mg/kg or exceed the highest dose tested (2000 mg/kg). A trend with ester chain length cannot be derived from the data.
Dermal effects
Dermal toxicity data are not available for all members of the category so read-across is required.
4.1.2.1. Dermal penetration and metabolism. Dermal effects are governed by 3 principles: 1. Dermal penetration of the ester or its cleavage products, 2. Metabolism within the skin primarily by carboxylesterases and 3. Evaporation. Data for the first two points are presented here and they have to be taken into consideration for all effects depending on the skin as barrier.
In vitro dermal penetration using epidermis and whole skin of rats and epidermis of humans has been investigated by Jones (2002) using MMA and selected esters with an alcohol moiety between C1-C12. Skin penetration clearly declines with increasing molecular weight and lipophilicity (logKow). The presence of carboxylesterases was demonstrated by the appearance of MAA in the receptor fluid after passage through whole viable rat skin. Ester cleavage during passage through whole skin was complete for n-BMA and the higher esters investigated (OMA and lauryl methacrylate). In contrast, after passage of MMA both the ester and MAA were found in the receptor fluid. Thus, for MMA the rate of absorption is higher than the rate of metabolism in epidermis while the reverse was true for n-BMA and the higher esters investigated. It could be shown that ester absorption through human skin is 10-20 times lower than through rat skin. Table 4 .
Systemic toxicity after dermal exposure is governed by the amount of ester passing through the stratum corneum reaching the underlying living cells and by ester cleavage. As discussed above, again this is a mix of scenarios 3 and 5 or 4 and 6. However, as evaporation is prevented by occlusive application, there will be a shift to scenarios 4 and 6 under these conditions. Dermal LD 50 values are available from guideline H.-P. Gelbke et al. Regulatory Toxicology and Pharmacology 92 (2018) 104-127 studies in rabbits for MMA and n-BMA (> 5000 and > 2000 mg/kg) and mortality was not observed at these doses. Although there are data gaps for EMA, i-BMA and 2-EHMA, for all methacrylate esters the acute dermal toxicity is expected to be low and the dermal LD 50 should at most be in the same range as the oral one (LD 50 for rats ≥9000 mg/kg) taking into consideration the extensive metabolism in the epidermis by ester hydrolysis, the low dermal penetration and the rapid ester hydrolysis after entering into systemic circulation. According to ECHA (2015, 2017a) a combination of scenarios 3/5 and 4/6 would apply. Because the LD 50 values were above the highest doses tested a trend cannot be established leading specifically to scenarios 5 or 6. In any case a low dermal toxicity is apparent. The uncertainty of this readacross is low according to the scheme of Blackburn and Stuard (2014) based on the low acute dermal toxicity of MMA and n-BMA in conjunction with the low acute oral toxicity of all group members (cf. electronic supplement). The MIE for sensitization is the potential hapten reaction with macromolecules (proteins) to form complete antigens. The low electrophilicity of the intact ester controls the Michael addition to macromolecules. The AOP for skin sensitization, namely macromolecular binding in the target cells, is therefore dependent upon absorption and electrophilic reaction of the intact ester, but a decision about the relative importance of both of these effects is not possible. MAA did not exhibit sensitization corresponding to the fact that MAA does not lead to Michael additions (EU RAR, 2002) . Therefore, whenever ester cleavage to MAA is taking place, this is a detoxification pathway with respect to sensitization.
The sensitizing potential of MMA was investigated in a large number of guinea pig studies (cf. ECETOC, 1995) and in the local lymph node assay (LLNA) (Betts et al., 2006) . The total database showed that MMA is a weak skin sensitizer. EMA and 2-EHMA appeared to give equivocal results in adjuvant studies in guinea pigs. The only test with i-BMA was negative, while n-BMA was positive in a guideline maximization test.
A series of LLNA studies in mice with different concentrations of EMA (Dony, 2013a) , i-BMA (Dony, 2013b) , n-BMA (Dony, 2013c ) and 2-EHMA (Dony, 2013d) confirmed the low sensitizing potency of these group members. The concentration of the test material leading to a 3-fold increase of cell proliferation induced nuclear labelling by [ 3 H] methyl thymidine in the local lymph nodes (EC 3 ) was taken as a quantitative indicator for the sensitizing potency. The EC 3 values were 41.4% for i-BMA, 43.6% for n-BMA, 82.6% for EMA and for 2-EHMA the EC 3 was not reached by the undiluted material. The EC 3 values indicated a low sensitizing potential. No clear response relationship with molecular weight could be derived for this small category. Considering the similar electrophilic reactivity of the esters that is only slightly decreasing with molecular weight as shown above for MMA, EMA and both butyl esters, one might have expected a trend of decreasing sensitizing potential with decreasing skin absorption and electrophilicity (increasing molecular weight). Since this is not the case, it is likely that other factors like metabolic detoxification (hydrolysis) in and evaporation from the skin may play a role, too. Overall the data do not indicate lack of support for the category and all observations taken together indicate that the lower methacrylate esters are at most weak skin sensitizers.
Respiratory sensitization
Data on respiratory sensitization is only available on MMA. With such limited data and the absence of valid experimental models for respiratory allergy of small molecular weight chemicals it is not possible to apply a category approach to this endpoint. Enoch et al. (2012) developed structural alerts based on specific reaction domains, including Michael reactivity, for respiratory sensitization based on similar grounds as reported by Enoch and Roberts (2013) for skin sensitization. They indicated that MMA, and by analogy other members of the category, might belong to the group of potential respiratory sensitizers. However, Borak et al. (2011) reviewed the in silico, in chemico, in vitro, and in vivo toxicology literature, and also epidemiologic and occupational medicine reports of MMA and concluded that the weight of evidence, both experimental and observational, indicates that MMA is not a respiratory sensitizer. Similarly, SCOEL (2005) concluded that there was no convincing evidence that MMA is a significant inducer of asthma in humans. SCOEL noted that taking into account that MMA is clearly a sensory irritant and that the majority of "asthmatic" respiratory responses had been associated with high exposures to MMA, the observations alleged to indicate respiratory sensitization may have come from respiratory irritation. Because the model of Enoch et al. (2012) does not take the rapid metabolic detoxification of MMA into consideration the conclusion of respiratory sensitization may be questioned, also based on the reviews of Borak et al. (2011) and SCOEL (2005) . Regarding the other esters of the category, there is no evidence in the clinical literature that they have been causally associated with respiratory allergy. Enoch et al. (2012) assigned the same structural alerts for respiratory sensitization to all methacrylate esters. The commonality in reaction domain might therefore suggest that these substances are expected to act similarly and scenario 4/6 would apply. Based on the trends for other endpoints, MMA may be expected a conservative source analogue. Thus, the rest of the category would at best be similar to MMA and not be respiratory sensitizers leading specifically to scenario 6. The uncertainty of this read-across is low to moderate according to the scheme of Blackburn and Stuard (2014) , mainly based on observation in humans and the analysis of structural alert (cf. electronic supplement).
Eye irritation
Eye irritation data in animals are available for all category members indicating slight irritation to the eyes of rabbits. This corresponds to the slight skin irritation of the members of this category under semi-occlusive application. With this complete data set a read-across is not necessary.
Effects after inhalation exposure

Inhalation metabolism/kinetics
Extensive ADME studies have been carried out on MMA including the development of a PBPK model for metabolism of MMA to MAA in nasal tissues. MMA is rapidly absorbed after inhalation (Bratt and Hathway, 1977; Bereznowski, 1995) . After inhalation exposure to rats, 10-20% of MMA is deposited in the upper respiratory tract (Morris, 1992) .
Former studies have shown that inhalation of MMA predominantly leads to destruction of the olfactory epithelium in the upper respiratory tract of rats. Studies with the carboxylesterase inhibitor bis-(p-nitrophenyl)phosphate (BNPP) have demonstrated that this is the consequence of intracellular ester cleavage to MAA, an irritant and corrosive metabolite (Mainwaring et al., 2001 ) leading to decreased intracellular pH. Under the assumption that ester cleavage and intracellular MAA drive local toxicity in the upper respiratory tract and by taking into account the distribution of carboxylesterases and the airflow pattern, the modelling by and Andersen et al. (2002) showed that humans are less sensitive than rats. In summarizing the available PBPK data on MMA, SCOEL (2005) concluded that human nasal olfactory epithelium will be at least 3 times less sensitive than that of rats to the toxicity of MMA. This difference in sensitivity stems from species differences in carboxylesterase activity and distribution of MMA to the olfactory epithelium. Carboxylesterases are heavily localized in the sustentacular cells and Bowman's glands of the rat olfactory region, but are more generally distributed in human olfactory epithelium. For the olfactory epithelium the maximum rate of metabolism in humans is about 13-fold lower than that in rats and for respiratory tissue at least 6-fold lower (Mainwaring et al., 2001) .
The systemic fate of the chemicals after inhalation exposure was modelled based on the clearance of the chemical from the local tissue. MAA was predicted to increase in blood during the 6 h exposure period but is thereafter rapidly cleared with a half-life of < 5 min. Comparing MMA, EMA, i-BMA and n-BMA by PBPK modelling, the highest MAA concentration was to be expected after MMA exposure and the highest concentrations of intact esters in blood for i-BMA. All esters were rapidly cleared from blood at the end of exposure in the model of Jones (2002 Table 5 .
Data for acute inhalation toxicity are available for all members, apart from 2-EHMA. For MMA and i-BMA only pre-guideline studies have been reported and for i-BMA only in mice while the other studies used rats. All studies point to a low acute inhalation toxicity with LC 50 values of ≥5,000 ppm. The LC 50 of i-BMA and n-BMA are somewhat lower than those of MMA and EMA. The LC 50 will be driven by local tissue destruction caused by intracellular formation of MAA and therefore corresponds to scenarios 3/5. This is governed for vapors by airflow over the surface, gas diffusivity and mucous-air partitioning (Jones, 2002) . On the other hand, for aerosols the aerodynamic diameter is the major determinant for the local impact within the respiratory tract (e.g. at larynx or further down in the respiratory tract). Therefore, a direct comparison and prediction of LC 50 values for vapors and aerosols becomes meaningless with alcohol side chain lengths beyond C4. On a mg/l basis, the LC 50 values of MMA (29.8 mg/l) and EMA (55 mg/l) are well below the calculated saturated vapor concentrations (cf. Table 1), but those of i-BMA and n-BMA (∼29 mg/l) are clearly above. Inhalation atmospheres at the concentration of the LC 50 of the butyl esters contain approximately 2/3 of aerosol and 1/3 of vapor.
No LC 50 value is available for 2-EHMA. Due to its low volatility the LC 50 will be much higher than the saturated vapor concentration (0.51 mg/l; 64.5 ppm, cf. Table 1 ). 2-EHMA will not be handled in a way that aerosols are routinely produced. As the systemic toxicity of all methacrylate esters is low, it may be assumed that inhalation toxicity of vapor/aerosol mixtures of 2-EHMA will be governed to a larger, albeit unknown extent by the local impact of the aerosol. While a science based estimate of a LC 50 in the aerosol range for higher esters like 2-EHMA was not possible, it could be deduced that the LC 50 will exceed the saturated vapor concentration of 2-EHMA by comparison to the other group members, i.e. corresponding to scenario 5. The uncertainty of this read-across is low for the conclusion that the LC 50 is above saturated vapor concentrations according to the scheme of Blackburn and Stuard (2014) but a quantitative estimate of the LC 50 for vapor/aerosol mixtures is not possible (cf. electronic supplement).
4.4.2.2. Acute respiratory irritation. Local lesions after acute inhalation exposure have been reported by Jones (2002) . Rats were exposed to 200 ppm of MMA, EMA, i-BMA and n-BMA for 6 h with subsequent histopathology of the nasal passages. 2-EHMA was not included because the inhalation atmosphere would contain high amounts of aerosol at this concentration (cf. Table 1) . No lesions were observed in the respiratory epithelium, the nasal region of the first impact of methacrylate vapors. On the other hand, exposure of MMA led to marked degeneration of the olfactory epithelium. Similar but slightly less severe effects were observed with EMA. The olfactory epithelium of rats exposed to i-BMA and n-BMA was not affected. Only at higher concentrations in a 4-week inhalation study, n-BMA led to slight degeneration of the olfactory epithelium starting at 952 ppm with a NOAEL at 310 ppm .
The specific location and the mechanism leading to the olfactory lesion are explained by the localized carboxylesterase mediated metabolism of the esters to MAA, an irritant and corrosive metabolite (Mainwaring et al., 2001) . The respiratory epithelium is not affected because it contains lower concentrations of carboxylesterases and is more richly perfused leading to a higher local clearance and lower tissue concentrations of MAA (Jones, 2002) . A combination of decreased partitioning and slower hydrolysis could explain why the butyl esters do not lead to olfactory degeneration in contrast to MMA and EMA. Since the mucous lining of the nasal epithelium is predominantly aqueous, decreasing water solubility of the esters (with the increasing chain length of the alcohol moiety) will result in decreased partitioning between air and aqueous mucous phases. This combined with a predicted slower hydrolysis rate would be consistent with the butyl esters being unable to elicit a toxic response. Likewise, no nasal toxicity is to be expected at a saturated vapor concentration of 2-EHMA.
These observations permit the assessment of the acute local cytotoxicity of MMA, EMA, i-BMA and n-BMA to the respiratory and olfactory epithelium at concentrations up to 200 ppm, which can be regarded as an exposure range most relevant to the workplace. The effects are driven by intracellular hydrolysis to MAA and therefore scenario 3 of ECHA (2015, 2017a) applies. Intracellular hydrolysis in the olfactory epithelium is anticipated to be much lower in humans compared to rats. Inhalation of 2-EHMA will follow the same mechanism with an even less pronounced local hydrolysis for example when compared to the butyl esters. Therefore, the uncertainty according to Blackburn and Stuard (2014) is low for the conclusion that 2-EHMA will not lead to nasal cytotoxicity at or above exposure that might be expected at the workplace (cf. electronic supplement).
Genotoxicity
The electrophilicity is considered an alert for Michael addition to DNA, however, electrophilicity of all methacrylate esters is regarded as being low. Furthermore, ester cleavage to MAA (and the alcohol) is a detoxification step resulting in metabolic products without expected mutagenic activity. Genotoxicity in in-vitro studies without metabolic activation is governed by electrophilicity that exhibits only a slight decrease with increasing molecular weight. Therefore scenario 6 of the RAAF applies as genotoxicity data generally are only used for a yes/no decisions while quantitative responses are of minor importance. With metabolic cleavage leading to MAA and the alcohols, both being devoid of electrophilicity, scenario 5 is appropriate, but there may be an overlap to scenario 6 due to incomplete ester cleavage in vitro. Also for H.-P. Gelbke et al. Regulatory Toxicology and Pharmacology 92 (2018) 104-127 genotoxicity in vivo with rapid ester cleavage in the organism, scenario 5 is predominant, but as at high exposures a fraction of the dose may escape metabolic detoxification, scenario 6 has also to be considered to a minor, unknown extent. Albertini (2017) reviewed the genotoxic profile of the lower alkyl methacrylate esters based on all in vivo and in vitro studies identified. The author concluded that a category approach for assessing genotoxicity is justified. Apart from the substances evaluated here, he also included 2-hydroxyethyl methacrylate. He concluded that for this group of chemicals, there is no convincing evidence for genotoxicity in vivo in either submammalian (clams, drosophila) or mammalian species, that they are universally negative for gene mutations in bacteria but do exhibit high dose clastogenicity in mammalian cells in vitro that can be explained by potential intermediates generated under these conditions. For clastogenicity he offered also another potential explanation, namely acidity caused by metabolic formation of MAA. It has been shown that cell culture conditions at low pH may lead to clastogenicity (e.g. Morita et al., 1989 Morita et al., , 1990 Morita et al., , 1992 Meintieres and Marzin, 2004) . Thus, shifts of intracellular pH caused by metabolism to MAA could trigger clastogenicity instead of direct reactions of methacrylate esters or their metabolites with DNA. Taking into account the review of Albertini (2017), genotoxicity is not further discussed here.
4.6. Repeated dose/prolonged exposure studies 4.6.1. General considerations For assignment of the scenarios proposed by ECHA (2015, 2017a) similar considerations apply as for acute toxicity in section 3. Due to the rapid ester cleavage, systemic effects will predominantly be driven by the body burden of MAA and the corresponding alcohol as long as the metabolic ester cleavage is not overwhelmed at high exposures. This would lead to scenario 3. A contribution of scenario 4 may also be considered, albeit to an unknown extent, at high exposures when ester hydrolysis is partly overwhelmed or first pass liver metabolism is circumvented by a fraction of the absorbed parent compound (i.e. after inhalation). High intracellular acidity caused by MAA after ester cleavage in epithelial cells at the portal of entry results in local effects corresponding to scenario 3 or 5 (scenario 5, if the local concentrations of MAA are not sufficient to cause cytotoxicity).
The dose metric to compare potency of the category members should reflect that systemic effects are mainly determined by the metabolic cleavage products within the body. Because of the large differences in molecular weight between MMA (100) and 2-EHMA (198) the same amounts on a weight basis of both substances will lead to completely different concentrations of MAA and the alcohols on a molar basis. Therefore, for the purpose of comparisons/predictions a dose metric reflecting molar concentrations should be used. Under these considerations the most appropriate approach would compare systemic NOAELs/LOAELs from oral studies based on mMol/kg/d and systemic and local effects after inhalation on ppm. For calculation of the systemic body burden, 100% absorption by oral and inhalation exposure is assumed as a simple approximation. The inhalation volume of rats is taken as 0.29 m 3 /kg/6 h (ECHA, 2012). Furthermore, any comparison/ prediction from different studies has to take into consideration uncertainties in numerical values of NOAELs/LOAELs caused by differences in dose spacing, protocols used, parameters examined, the interpretation of effects as being toxicologically relevant or not, etc. Therefore, even with a scientifically defensible dose metric, such dose comparisons and predictions will only be valid within the boundaries of numerical NOAELs/LOAELs. To avoid the impression of unjustified precisions for the predictions of NOAELs in subchronic/chronic studies with their different potential target organs, spans are given that would cover the "real" NOAELs reflecting the uncertainties of this approach. But nevertheless, such spans are a valid basis for risk assessment considerations and the lower boundaries will correspond to the most conservative estimate. For reproductive studies with their clearly defined endpoints, direct intra-/extrapolations are better justified.
The basic assumption of this category approach is that, given the data on metabolism summarized above, systemic toxicity of methacrylate esters is determined by the parent ester or by MAA (as a common metabolite of all members), or a combination thereof, while the different alcohols are not expected to play a decisive role. The intact esters may have some influence on the toxicological profile, which is assumed to be of minor importance due to the rapid ester cleavage, especially for the relatively low oral and inhalation exposures prevailing for humans. Furthermore, electrophilicity of the intact esters will only show minor variations within this group. But as already indicated above, at high doses and after inhalation small but unknown amounts of intact ester may be available systemically by escaping first pass liver metabolism that may then undergo ester cleavage in blood and other tissues.
If the assumption above holds true, the NOAELs obtained for the esters (that may be impacted to a small extent by their low electrophilicity) should be lower than those of the alcohols based on the dose metric taking into account the different molecular weights. To prove this hypothesis, we compared the experimental NOAELs obtained in multiple dose studies with rats for the methacrylate esters and their respective alcohols. In addition, if the NOAELs and LOAELs allowed it, we investigated whether specific organ toxicity exerted by alcohols and methacrylate esters contradicts this hypothesis. Data gaps were filled in by intra-or extrapolation. We also examined whether, at the NOAELs thereby derived, toxic effects may be expected from the alcohol metabolites formed.
Repeated dose studies
In Table 6 the observed and predicted NOAELs of the methacrylate esters for systemic and local repeated dose toxicity in rats after inhalation and oral exposure are summarized. In addition, systemic NOAELs of the corresponding alcohols are given. If the NOAEL did not correspond to the highest dose tested, the findings at the next higher dose (LOAEL) are given and listed in Table 7 . There are studies available for many, but not all of the category members. For MAA a 90 d inhalation study has been performed. For MMA drinking water and inhalation studies of up to a 2-year duration have been carried out. A 28 day inhalation study with n-BMA and oral studies up to 90 d for n-BMA and 2-EHMA are available. In addition, there are oral OECD TG 422 combined repeated dose reproductive/developmental screening studies for n-BMA and 2-EHMA.
Oral studies
MMA: In a 2-year, 2-species chronic drinking water study with MMA no adverse effects were observed other than an initial depression of body weight and food consumption. Elevated kidney weights without corresponding histopathology were found in female rats at 2000 ppm (the highest dose tested) that may be regarded as the NOAEL (164 and 124 mg/kg/d in male and female rats corresponding to 1.64 and 1.24 mMol/kg/d) (Borzelleca et al., 1964) . n-BMA: In an OECD TG 422 combined repeated dose and reproductive/developmental toxicity screening test, rats dosed orally showed, apart from decreased body weight at the highest dose level, signs of toxicity in the kidney and spleen (Ito et al., 1998) . The NOAELs were originally considered to be 30 mg/kg/d for males and 300 mg/kg/ d for females. A later independent review showed that effects seen in males were not statistically significant when compared with published historical control data from the same laboratory and the NOAEL of this study was revised to 300 mg/kg/d (2.11 mMol/kg/d) (RSA, 2008) . Taking into consideration historical control data this independent review concluded that the LOAEL was 1000 mg/kg/d (7 mMol/kg/d) with the following findings of toxicological relevance: decreased body weight (males 10.5%, females 18.4% at necropsy) and food consumption in males and females, atrophy of the splenic red pulp in males and females, and increases in urea nitrogen in the blood of males.
A guideline 90-day gavage study in rats with n-BMA with a recovery period of 28 days showed signs of liver and kidney toxicity (both sexes) with increased relative weights, apart from decreased body weight and body weight change (−12.1%, males) at 360 mg/kg/d, the highest dose tested (BASF, 2009 ). Thus, in comparison the screening study of Ito et al. et al. (1998) , kidney effects were verified at a lower dose level, but there were no indications of effects on the spleen that was affected in the study of Ito et al. (1998) at a higher dose level. Local degenerative and regenerative effects in the olfactory epithelium of the nasal cavity were observed at 120 and 360 mg/kg/d in both males and females that were fully reversible within a 28 day recovery period. The histopathological picture of the lesion did not allow a decision as to whether this was a secondary effect due to the application procedure or caused by exhalation of the test material through the lung. Considering the short half-life of n-BMA in blood (99.7% removed in first pass by the liver, Jones, 2002) it is unlikely that these effects were of systemic origin, but were rather local effects as the oral dosing may lead to some exhalation exposure as a result of regurgitation/reflux from the stomach (Sells et al., 2007) . The overall NOAEL for systemic toxicity was 120 mg/kg/d (0.85 mMol/kg/d) for the Ito et al. and BASF studies and the LOAEL was 360 mg/kg/d based on the 90-day BASF (2009) study.
2-EHMA: In an oral toxicity study in rats using the OECD TG 422 protocol, the main findings at the LOAEL of 300 mg/kg/d were increased liver and kidney weights in males and females (Furuhashi et al., 1998) . The relative kidney weights were already reported to be increased in females at 100 mg/kg/d. After independent review and comparison with historical data from this laboratory, the NOAEL of this study was found to be 100 mg/kg/d (0.51 mMol/kg/d) (RSA, 2008a) .
Also with 2-EHMA a 90-day gavage study was performed in Wistar rats with a recovery period of 28 days (BASF, 2009a) . This study revealed in females effects on body weight, body weight gain and reduced food intake presumably due to palatability at 360 mg/kg/d (1.83 mMol/kg/d), the highest dose tested. Effects on the liver and kidney were not noted at 360 mg/kg/d. In addition, transient changes in blood chemistry were found. The NOAEL of the study was 120 mg/kg/d (0.61 mMol/kg/day). Taken together, the NOAEL of both studies is 120 mg/ kg/d and the LOAEL was 300 mg/kg/d based on Furuhashi et al. (1998) .
None of these studies reported irritation of the gastro-intestinal tract supporting the concept that ester cleavage and subsequent systemic distribution of MAA occur rapidly.
Inhalation studies
MAA: In an OECD 413 90-day inhalation study with rats general toxicity was noted at 350 ppm (the highest concentration tested) in both sexes (decreased body weights). In females local marginal irritation of the respiratory epithelium in the nasal cavity was observed in two animals. Apart from effects on body weight that might be related to nasal irritation there were no further indications for systemic toxicity. The NOAEL was 100 ppm for local and systemic effects (BASF, 2008) corresponding to 95 mg/kg/d and 1.1 mMol/kg/d.
MMA: The US National Toxicology Program conducted inhalation studies of 14 and 104 weeks duration in rats and mice (NTP, 1986; Chan et al., 1988) . In the 14-week study with exposure concentrations up to 5000 ppm, the systemic NOAEL was 1000 ppm for male rats (based on body weight) and 500 ppm for females (based on histopathological findings in the brain). In mice reduced body weight was observed down to the lowest exposure group (500 ppm) and the NOAEL for kidney effects was 1000 ppm in males. The two-year study was conducted at 0, 500 and 1000 ppm (male rats, male and female mice) and at 0, 250 and 500 ppm for female rats. In mice reduced body weight (probably secondary to the local irritation) occurred at both dose levels and findings indicative of clear systemic toxicity were not noted. Reduced mean body weights in male and female rats were observed at 500 ppm without any further pathological findings. Therefore the reduced body weights at 500 ppm were likely a secondary consequence of the local nasal lesion and 500 ppm may be regarded as NOAEL for systemic effects in both species. But because of the uncertainty about the relevance of the reduced body weights a conservative approach would take 500 ppm as LOAEL for mice and male rats and 250 ppm as NOAEL for female rats. Local effects on the nasal respiratory and olfactory tract were seen in rats and mice in the 14-and 104-week-studies. These included inflammation of the nasal cavity and most prominently degeneration of the olfactory epithelium at all dose levels, i.e. down to 250 ppm in female rats. A NOAEL for local effects could not be established. Because of the uncertainties regarding the local and systemic NOAELs of the NTP (1986) study the NOAELs will here be defined by the lower dose levels of the study of Lomax et al. (1997) with rats and hamsters. This is a carcinogenicity study by inhalation with MMA in rats (duration 24 months) and hamsters (duration 18 months) at 0, 25, 100 and 400 ppm with interim sacrifices after 13 and 52 weeks. Systemic effects were only noted at 400 ppm, namely decreased body weights in hamsters and female rats and increased mortality of male hamsters that might be related to nasal irritation. The systemic NOAEL was 100 ppm, corresponding to 112 mg/kg/d and 1.12 mMol/kg/d. At the end of exposure, rats (both sexes) showed histopathological lesions of the olfactory epithelium at 100 and 400 ppm and of the respiratory epithelium at 400 ppm giving a local NOAEL of 25 ppm. No nasal lesions were found in hamsters. An important finding is that hamsters, in contrast to rats and mice, do not respond to MMA inhalation by nasal toxicity. According to Jones (2002) , species differences in sensitivity may stem from differences in amounts and location of carboxylesterases and from differences in air flow pattern. The specific factors leading to the insensitivity of hamsters are unknown, but for humans both factors suggested by Jones point to a decreased sensitivity of human olfactory epithelium in comparison to rats, i.e. a lower activity of carboxylesterase (Mainwaring et al., 2001 ) and air flow pattern with smaller local exposure to the olfactory region of humans . Hext et al. (2001) studied the time course of development and reversibility of nasal toxicity in rats exposed to MMA at 110 and 400 ppm up to 28 consecutive days with several interim sacrifices followed by a recovery period of up to 13 weeks. At 110 ppm already after 1 and 2 days of exposure, minimal degeneration/necrosis of the olfactory epithelium was noted. These initial effects were rapidly repaired, even under further exposure, such that full recovery had occurred after 28 days of exposure. At 400 ppm over 28 days minimal to slight degeneration of the olfactory epithelium was observed with signs of regeneration and disorganized epithelium at different intervals during exposure. The majority of the olfactory epithelium had returned to normal within 13 weeks of recovery. No olfactory lesions were observed at 110 ppm after a recovery phase of 1 month. The authors provide examples of other chemicals leading to similar effects with regeneration during exposure of the olfactory epithelium. Thus, toxicity to the olfactory epithelium was reversible at 110 ppm already during exposure. A comparison of the results of Lomax et al. (1997) and of Hext et al. (2001) shows that the slight and reversible effects at 110 ppm described by Hext during 28 days may persist or may even increase during life time exposure, but 25 ppm would represent a clear NOAEL for the nasal cavity. Unfortunately a comparison of the severity of the nasal lesions is not possible as no grading was given by Lomax. Thus, there was a difference by a factor of about 4 between the LOAEL for slight reversible local effects during the 28 days exposure period and the NOAEL after 2 years. n-BMA: In an OECD Guideline 412 28-day inhalation study increased relative kidney weights of both sexes at 1891 ppm (the highest concentration tested) determined the NOAEL for systemic effects of 952 ppm, corresponding to 1560 mg/kg/d and 11 mMol/kg/d . It is noted that the indications for effects on kidneys corresponded to those by Ito et al. (1998) and BASF (2008) after oral exposure at lower systemic doses. The different LOAELs may be explained by the lower numbers of animals (5 males and 5 females) in the study of Hagan while the oral studies used 10 animals/sex/dose. Local effects of slight degeneration of the olfactory epithelium started at 952 ppm with clinical signs of irritation. The local NOAEL was 310 ppm. It should be noted that the highest exposure concentration of 1891 ppm is very close to the calculated saturated vapor concentration of ∼2100 ppm (Table 1 ) so the possibility of aerosol formation cannot be excluded.
Comparison of methacrylate esters and their alcohols
The data available for methacrylate esters and their respective alcohols are summarized in Table 6 (NOAELs) and Table 7 (effects); the data for the alcohols are taken from the REACH registration dossiers (ECHA, 2017b) .
MMA vs. methanol: There is no valid oral 2 year study available for methanol. For inhalation exposure of rats, the systemic NOAELs are 100 ppm both for MMA and methanol in 2 year inhalation studies with detailed investigations for methanol after 12 months. The exposure schedules were different, 6 h/d, 5 d/week for MMA and 20 h/d, 7 d/ week for methanol. Therefore the integrated systemic dose at the H.-P. Gelbke et al. Regulatory Toxicology and Pharmacology 92 (2018) 104-127 NOAEL is by a factor of about 4.5 higher for methanol (∼5.1 mMol/kg/ d) than for MMA (1.12 mMol/kg/d). At the next higher dose level of 400 ppm (4.5 mMol/kg/d), MMA only led to a decreased body weight after 52 weeks, possibly related to local irritation. For methanol the next exposure concentration was by a factor of 10 higher, i.e. 1000 ppm (51 mMol/kg/d). Apart from a transient slight depression of body weight there were some findings that could be considered as treatment related (e.g. slight increase of relative liver and spleen weight), but due to their minor degree and severity it was concluded that these effects could be considered as toxicologically irrelevant without a pathological meaning. Overall, a conservative NOAEL for methanol would be 100 ppm (corresponding to ∼5.1 mMol/kg/d by correction for the different exposure schedule) with only unspecific signs of toxicity. n-BMA vs. n-butanol: OECD TG 422 or 28 day studies are not available for n-butanol. In an oral 90 day study, the NOAEL of n-butanol was 1.7 mMol/kg/d (125 mg/kg/d) and thereby clearly higher than the NOAEL for n-BMA (0.85 mMol/kg/d). At the next higher dose level (360 mg/kg/d; 2.54 mMol/kg/d) n-BMA led to reduced body weight in males and slight liver and kidney toxicity. The next dose level of n-butanol was 500 mg/kg/d (6.8 mMol/kg/d, the highest dose tested) leading during the last weeks of exposure to ataxia and hypoactivity directly after dosing that rapidly subsided within one hour (both sexes). In addition some minor effects on red blood cells were described in females only. Taking into account the different dose levels on a molar basis and the slight effects noted, these findings do not indicate a difference in specific organ toxicity caused by n-BMA and nbutanol. Supporting evidence that the toxicity of n-BMA is not driven by the alcohol component can be derived from a 90 day inhalation study with n-butyl acetate, a chemical that is rapidly metabolically hydrolyzed to n-butanol and acetic acid. In this study the NOAEL was 500 ppm corresponding to an even higher body burden of 6.1 mMol/ kg/d for n-butanol than that observed in the oral study. At the next exposure concentration of 1500 ppm (18.3 mMol/kg/d), the most prominent effects were decreased body weights and relative spleen weights of both sexes. The effects noted for the spleen correspond qualitatively to those described by Ito et al. (1998) . In addition, local effects in the form of olfactory necrosis were observed in both sexes. This extrapolation from n-butyl acetate to n-butanol was used by OECD (2001). The NOAELs for the 28 day studies with n-BMA (oral 2.11 mMol/kg/d; inhalation 952 ppm or 11 mMol/kg/d) are somewhat higher than those of the corresponding 90 day studies with n-BMA and n-butanol, but this can be explained by different exposure durations, spacing of dose levels, number of animals and parameters examined.
2-EHMA vs. 2-ethylhexanol: OECD TG 422 or 28 day studies are not available for 2-ethylhexanol but two 90 day studies. The body burden at the NOAEL was 1.42 mMol/kg/d (120 ppm) after inhalation, the highest dose tested, and after oral application 0.96 mMol/kg/d (125 mg/kg/d). In the oral study the LOAEL was 250 mg/kg/d with increased relative organ weights of liver and kidney (both sexes). At the highest dose level of 500 mg/kg/d some males and females showed histopathological effects in the liver. The body burdens at the NOAELs of 2-ethylhexanol were clearly higher than those after oral application of 2-EHMA over 28 days (0.51 mMol/kg/d) or 90 days (0.61 mMol/kg/ d). A comparison of target organ toxicity shows for the oral 90 day studies that the LOAEL of 2-EHMA at 1.8 mMol/kg/d (360 mg/kg/d) was determined by reversible changes in clinical chemistry and a reduced body weight in females. 2-Ethylhexanol led at 1.9 mMol/kg/d (250 mg/kg/d) to an increase of liver and kidney weights that became more pronounced at the next higher dose level of 3.8 mMol/kg/d. Thus, liver and kidney were clearly the target organs of 2-ethylhexanol that were not affected by 2-EHMA at a similar dose level. But this finding cannot be taken as an indication that 2-ethylhexanol affects different target organs as compared to 2-EHMA, as in both studies different rat strains were used, for 2-ethylhexanol Fischer 344 and for 2-EHMA Wistar rats. In the OECD TG 422 study of Furuhashi et al. (1998) with 2-EHMA, liver and kidney weights were affected at the LOAEL of 300 mg/ kg/d with Sprague-Dawley rats. Another possibility could be the protracted release of 2-EHMA from adipose tissue leading to a retarded liberation of 2-ethylhexanol although the extensive first pass liver metabolism of 2-EHMA once released from the adipose compartment would suggest that this is less likely. By all means, target organ toxicity seemed to be less pronounced for 2-EHMA as compared to 2-ethylhexanol.
In summary, neither the NOAELs/LOAELs nor specific organ toxicity indicate that the toxicological profile of methacrylate esters is governed by their alcohol moieties. Therefore, the toxicological profile of methacrylate esters is driven by MAA or to a lesser extent by transient, unmetabolized ester.
Summary and discussion of repeated dose toxicity by oral and inhalation exposure
The basic assumption for repeated dose toxicity is that, due to the relatively short half-life of the parent ester within the body, systemic effects after oral and inhalation exposure are mainly driven by the products of ester hydrolysis, namely MAA and the corresponding alcohols. Local effects after inhalation are determined by local release of MAA, generally to the olfactory epithelium leading to cytotoxicity due to intracellular acidity. This corresponds to scenario 3 of ECHA (2015, 2017a) .
The NOAELs obtained in repeated dose rat studies are summarized in Table 6 and the effects observed at the LOAEL in Table 7 . The studies comprise exposure durations from 28 days to 2 years and in general the NOAELs (based on mMol/kg/d) are very similar, apart from the higher one of the 28 day inhalation study of Hagan et al. (1993) with n-BMA. As there appears to be no marked influence of exposure duration on NOAELs, the read-across to fill in data gaps may well encompass exposure durations up to 2 years and a conservative approach would certainly allow predictions up to 90 days.
For oral exposure the systemic NOAELs for the three substances with experimental data (MMA, n-BMA and 2-EHMA) are in the range of 100-300 mg/kg/d. On a mMol/kg/d basis they are comparable taking into account all uncertainties surrounding numerical values of NOAELs noted above. The range is about 0.5-1.5 mMol/kg/d; the NOAEL of the OECD TG 422 study for n-BMA with shorter duration is slightly higher as is to be expected. By interpolation within the category it would be expected that EMA and i-BMA would also have comparable NOAELs in the range of 0.5-1.5 mMol/kg/d. The same can be assumed for MAA, the common metabolite. Estimates in mg/kg/d are then derived on the basis of the molecular weights for the category members with data gaps leading to ranges of interpolated NOAELs after oral exposure of 40-130 mg/kg/d for MAA, 60-170 for EMA and 70-200 for i-BMA.
Systemic NOAELs for MAA and MMA after inhalation are 1.1 mMol/ kg/d, in the same range as after oral exposure. This supports the notion that systemic effects at both exposure routes, oral and inhalation, are driven by MAA, the common systemic metabolite. But the NOAEL for n-BMA is clearly higher (11 mMol/kg/d), which may in the first place be explained by the shorter exposure duration and the limited parameters investigated in a 28 day study in comparison to the 90 day study with MAA and the 2 year study with MMA. Another possibility could be that a slower release of n-BMA from adipose tissue could lead to a protracted liberation of MAA from n-BMA. Therefore a conservative approach could assume for all lower methacrylate esters a NOAEL for systemic toxicity after inhalation of 1 mMol/kg/d by extrapolation from MMA and MAA. This corresponds for EMA, i-BMA and 2-EHMA to about 90 ppm, already above the saturated vapor concentration of 2-EHMA. This NOAEL is also accommodated to n-BMA for prolonged exposure durations of 90 days and above.
Predicted NOAELs for systemic effects are based on a dose range of 0.5-1.5 mMol/kg/d for oral exposure and of 1 mMol/kg/d for inhalation. If the assumption is correct that toxicity of the lower methacrylate esters is not driven by the alcohols generated by metabolic cleavage, it has to be ascertained that the NOAELs of the alcohols are above this H.-P. Gelbke et al. Regulatory Toxicology and Pharmacology 92 (2018) 104-127 range. For ethanol a NOAEL of 1730 mg/kg/d, corresponding to 37.6 mMol/kg/d, was identified in a 14 week gavage study with rats based on kidney effects at 3160 mg/kg/d. In the key study for i-butanol the highest dose level of 16,000 ppm in drinking water was the NOAEL in a 90 day study with rats, corresponding to 1450 mg/kg/d or 19.6 mMol/ kg/d. For 2-ethylhexanol a NOAEL of 125 mg/kg/d, corresponding to 0.96 mMol/kg/d, was identified in a 90 day gavage study with rats based on effects on liver and kidney weights at 1.9 mMol/kg/d (LOAEL). A somewhat higher systemic NOAEL of 1.42 mMol/kg/d (120 ppm) was obtained in a 90 day inhalation study, the highest exposure concentration tested. But the NOAEL after inhalation was below the LOAEL after oral dosing. These data show that on a mMol/kg/d basis the NOAELs for ethanol and i-butanol are far above the NOAELs derived for EMA and i-BMA by interpolation from MMA and n-BMA for systemic effects after oral and inhalation exposure. For 2-ethylhexanol the NOAEL is in the same range of (oral) or slightly above (inhalation) the NOAEL of 2-EHMA derived by extrapolation for systemic effects after inhalation exposure. This comparison with repeated dose toxicity data of the alcohols supports the validity of the approach used to fill in data gaps for the lower methacrylate esters. For the inhalation route, local effects represent the most sensitive endpoint. Inhalation of MAA causes slight local irritation of the nasal respiratory epithelium with a NOAEL of 100 ppm after 90 days, while the NOAEL for n-BMA is 310 ppm (28 days). The primary irritation potential of the esters is less than that of the acid, but due to their higher lipophilicity they are absorbed more efficiently in the posterior (olfactory) region of the nasal cavity where they are hydrolyzed by carboxylesterases. In the case of MMA, the ester for which the most extensive inhalation data are available, there appears to be only a slight decrease in NOAEL from acute exposures of 6 h up to two years. It has been shown that the NOAELs of the higher esters for the olfactory lesion increase with molecular weight. Data available for MMA and n-BMA with repeated exposures support this hypothesis as well as the acute inhalation data of Jones (2002) for MMA, EMA, n-BMA, and i-BMA.
An appropriate basis for inter-and extrapolation are the findings of Jones (2002) . After a single exposure to 200 ppm, nasal lesions occurred with MMA and EMA (slightly less) but not with i-BMA and n-BMA. Therefore for repeated inhalation exposure to EMA a conservative chronic local NOAEL can be defined at 25 ppm in direct analogy to MMA. For i-BMA and 2-EHMA a NOAEL of 310 ppm can be extrapolated from that of the 28 day study with n-BMA. But as the comparison of the data of Lomax et al. (1997) (NOAEL of 25 ppm after 2 years) and Hext et al. (2001) (LOAEL of 110 ppm within 28 days with marginal, reversible effects) indicate that a slight aggravation of local effects for MMA with prolongation of exposure may occur, a factor of 2 may be applied leading to a chronic NOAEL of ∼150 ppm for n-BMA, i-BMA and 2-EHMA. This conservative approach suggests that the local effect of MMA after repeated exposure may be directly transferred to EMA and that of n-BMA to i-BMA and 2-EHMA. For 2-EHMA the saturated vapor concentration (∼65 ppm) would be clearly below the concentrations expected to lead to nasal lesions in rats extrapolated for vapor exposure.
Local effects of methacrylate esters are driven by ester cleavage leading to highly cytotoxic intracellular MAA. In relation to MAA the irritating potential of the alcohol moieties is negligible. Therefore for local effects after inhalation, a comparison between methacrylate esters and their corresponding alcohols is not necessary.
The uncertainty associated with inter-and extrapolation of NOAELs for systemic effects after oral and inhalation exposure and local effects after inhalation is low according to the scheme of Blackburn and Stuard (2014) (cf. electronic supplement). Apart from the general considerations in section 2.6., this assessment is based on the number of studies available (mostly following present days' guidelines), the unspecific signs of non-life threatening systemic toxicity at relatively high oral doses, and for local effects after inhalation the clear dependency on molecular weight after acute exposure. In addition, systemic toxicity was not driven by the alcohols after ester hydrolysis.
Carcinogenicity
The potential mechanisms for carcinogenicity by methacrylic esters are different for systemic and local effects at the portal of entry. Due to the rapid ester cleavage by carboxylesterases, systemic carcinogenicity could only be governed by MAA and the respective alcohols that are non-genotoxic. Local carcinogenicity may be driven by two mechanisms: 1) Electrophilic reaction of the intact esters with DNA corresponding to scenario 4 of ECHA (2015, 2017a) , but this mechanism does not play an important role as methacrylic esters do not exhibit a pronounced electrophilicity which is supported by their lack of mutagenicity in in-vitro and in-vivo systems. 2) Ester cleavage (scenario 3 of ECHA) with local cytotoxic accumulation of MAA that may in principle result in tumor formation by a non-genotoxic mode of action, i.e. increased cell proliferation induced by cytotoxicity. A pronounced local irritation has not been observed after oral or dermal exposure and for these exposure routes this second mechanism is not expected to be relevant. On the other hand, inhalation of MMA and to a lesser extent of EMA leads to cytotoxicity in the olfactory epithelium, and therefore this mechanism might in theory play a role for the inhalation route.
Carcinogenicity studies are only available for MMA. In a 2-year drinking water study with rats, conducted prior to current guidelines, no local or systemic carcinogenic effect was found at doses up to 2000 ppm (Borzelleca et al., 1964) leading to a body burden of 1.64 and 1.24 mMol/kg/d for male and female rats. Similarly, no carcinogenic response was observed at inhalation exposures up to 400 ppm in rats exposed over 2 years and hamsters over 78 weeks (Lomax et al., 1997) . Nasal lesions occurred in rats at 100 and 400 ppm but not in hamsters. Even higher concentrations up to 1000 ppm (male rats, male and female mice) or 500 ppm (female rats) did not lead to increased tumor incidences, while non-neoplastic local lesions were observed in both species (NTP, 1986; Chan et al., 1988) . The systemic body burden after inhalation (11.2 mMol/kg/d at 1000 ppm for male rats and 5.6 mMol/ kg/d at 500 ppm for female rats) is much higher than that achieved in the drinking water study. Thus, after ester hydrolysis MAA is not expected to lead to systemic tumors at such high body burdens and scenario 5 of ECHA (2015, 2017a) did not result in a carcinogenic response.
Comparison of MMA with methanol
The carcinogenicity study of MMA by inhalation (NTP, 1986; Chan et al., 1988) can directly be compared to a negative carcinogenicity study with methanol up to 1000 ppm (OECD, 2004b) . As here exposure to methanol was maintained for 7 d/week, 20 h/d, the integrated body burden of methanol was by a factor of about 4.5 higher than that after MMA exposure (5 d/week, 6 h/d). Thus, the NOAEL for a carcinogenic response is higher for methanol than for MMA.
Extrapolation to the other group members
Based on the common metabolite MAA, the lack of a systemic carcinogenic effect of MMA can be extrapolated to the other members of the group according to scenario 5 of ECHA (2015, 2017a) . Their noncarcinogenicity is further supported by the negative data base for genotoxicity and mutagenicity (scenario 6 of ECHA, 2015, 2017a). As inhalation of MMA leads to the most prominent local effects, a neoplastic response in the upper respiratory tract driven by chronic irritation is not to be expected for the other lower methacrylate esters at inhalation concentrations up to 1000 ppm. But the question remains whether systemic tumors may occur in potential carcinogenicity studies with exposures up to the maximal tolerable dose (MTD). Because the database is more robust for rats than for mice the following considerations will concentrate on the rat.
Theoretical derivation of a MTD is relatively straight forward for EMA. Local nasal toxicity of EMA is slightly less pronounced than that of MMA. In rats exposed to MMA over 2 years histopathological lesions in the nose started at 100 ppm while at 500 and 1000 ppm local inflammation and degeneration were observed in all exposed female and male animals. Therefore 1000 ppm would be an appropriate MTD for EMA, corresponding to a systemic dose of 11.2 mMol/kg/d as for MMA. At this concentration MAA formed by metabolic cleavage of MMA did not lead to systemic tumors in male rats. For ethanol an oral rat study is reported on the ECHA (2017b) website without a carcinogenic response at 3 g/kg/d, corresponding to 65 mMol/kg/d. Thus, neither a local nor a systemic carcinogenic response is to be expected for EMA at a theoretical MTD concentration of 1000 ppm.
No carcinogenicity studies were identified for n-and i-butanol from the ECHA (2017b) website. There is only a "weight of evidence" entry that i-butanol does not contain structural biophores for a carcinogenic potential. This conclusion was derived from a QSAR-model (Quantitative Structure Activity Relationship) (Rosenkranz and Klopman, 1990) and adds further confidence to the assessment based on the negative genotoxicity database of the methacrylate esters. In total, there is some good but indirect evidence that n-BMA and i-BMA are not carcinogenic.
The saturated vapor concentration of 2-EHMA is 64.5 ppm (Table 1) . Therefore an inhalation study with concentrations similar to that with MMA is not possible and assessment of carcinogenicity would only be feasible by the oral route apart from exposure to extremely high (and irrelevant) aerosol concentrations. In the 90-day gavage study with 2-EHMA the NOAEL was 120 mg/kg/d and the LOAEL 360 mg/ kg/d based on signs of general systemic toxicity. This LOAEL would be a well justified MTD, corresponding to 1.8 mMol/kg/d. In the key carcinogenicity study with 2-ethylhexanol on the ECHA (2017b) website a neoplastic response was not observed up to a dose level of 500 mg/kg/d by gavage application, corresponding to 3.8 mMol/kg/d 2-ethylhexanol. Thus, a potential oral carcinogenicity study with 2-EHMA at the MTD is not expected to lead to systemic tumors by the body burdens of 2-ethylhexanol or MAA.
In summary, there is good evidence that the lower methacrylate esters will not lead to a carcinogenic response at exposure levels up to their MTD.
Reproductive toxicity
In general, only chemicals reaching the systemic circulation can induce reproductive or developmental effects. Therefore, due to the rapid ester cleavage these effects will be predominantly governed by the body burden of MAA and the corresponding alcohol corresponding to scenario 3 of ECHA (2015, 2017a) but a small temporary contribution of intact ester (scenario 4) may also be considered. Local effects that may stem from intact esters or ester cleavage products can only play a role for dose selection. In case the doses selected lead to severe local irritation this may eventually confound the interpretation of true reproductive or developmental effects. Inoue et al. (2007) studied 20 chemicals in vitro for their binding to receptors that may interfere at various stages of the reproductive cycle, namely estrogen receptor α, thyroid hormone receptor α, retinoic acid receptor γ, retinoic X receptor α, vitamin D receptor, peroxisome proliferator-activated receptor α, β and γ. Esters of MAA were not included in this series, but MAA itself, the common metabolite of all methacrylate esters, did not exhibit an affinity to any of these receptors.
Fertility
In Table 8 the observed and predicted NOAELs of the methacrylate esters for effects on fertility in rats after inhalation and oral exposure are summarized. In addition, the NOAELs of the corresponding alcohols are listed. Information on fertility parameters can be derived by test protocols of different levels of complexity from screening studies for reproductive effects to 2-generation studies. In addition, repeated dose studies with histopathology of the reproductive organs provide another tool for detecting potential impairment of fertility. The following studies are available for the members of the category: A guideline oral two-generation reproductive toxicity study for MMA, in vivo oral reproductive/developmental toxicity screening studies (OECD TG 422) for n-BMA and 2-EHMA; repeated dose 90-day oral studies with detailed histopathology of the reproductive organs for n-BMA and 2-EHMA and by inhalation with MAA (90 days) and MMA (13, 52 weeks). Apart from the repeated dose inhalation studies with MAA and MMA, all other investigations used the oral route. Findings at termination of 2-year studies should not be used for assessment of reproductive effects due to potential confounding by age related alterations.
MAA: A 90-day inhalation study included histopathology and weight of the reproductive organs as well as sperm parameters. The NOAEL was 100 ppm for local and systemic effects and 350 ppm for parameters related to fertility (corresponding to 3.9 mMol/kg/d), the highest dose tested.
MMA: In an oral two-generation reproduction toxicity study in rats there were no signs of systemic toxicity other than reduced body weight gain in F1 animals (males: 6-17% depending on age; females: up to 16% during premating) associated with reduced food consumption (males: 7-14%; females 8-10%), presumably due to palatability. The NOAEL for fertility and reproductive performance for the F0 and F1 parental rats was 400 mg/kg/day (corresponding to 4 mMol/kg/d), the highest dose tested (BASF, 2010) .
A carcinogenicity study in rats by inhalation included subgroups sacrificed after 13 and 52 weeks of exposure to MMA, testes and ovaries were weighed and subjected to histopathology. No abnormal findings were recorded in the gonads. The NOAEL for gonadal effects was 400 ppm, the highest dose tested (corresponding to 4.5 mMol/kg/d) that only led to local effects in the nasal cavity (Lomax et al., 1997) .
n-BMA: An oral OECD TG 422 screening study with rats which included assessments of reproductive and developmental toxicity parameters reported decreases in numbers of corpora lutea and implantations in parental females in the high dose group. These findings were accompanied by an excessive decrease in body weights of females in this group (18.4% at necropsy). Thus, the NOAEL for reproductive toxicity was considered to be 1000 mg/kg/d (7.0 mMol/kg/d) for parental males and conservatively 300 mg/kg/d (corresponding to 2.11 mMol/kg/d) for parental females (Ito et al., 1998) . In this study the NOAEL is determined by effects noted in females after pregnancy.
Organ weights and detailed histopathology of the reproductive tissues revealed no adverse effects at the highest dose in the 90 day oral n-BMA study in the presence of reduced body weight (males) and increased kidney weights apart from some changes noted in clinical pathology. The overall NOAEL for systemic toxicity was 120 mg/kg/d and 360 mg/kg/d (corresponding to 2.53 mMol/kg/d) for the reproductive system (BASF, 2009) .
No effects related to fertility were observed in a 28-day inhalation study in rats. The overall NOAEL was 310 ppm based on degeneration of the olfactory epithelium and the NOAEL for histopathology of the reproductive organs was 1891 ppm, the highest dose tested . But this NOAEL must be interpreted with caution and may only be used as supportive evidence, as the duration of exposure over 28 days does not cover the whole spermatogenic cycle.
2-EHMA: In an oral OECD TG 422 screening study maternal toxicity and effects on reproductive parameters were observed at the highest dose of 1000 mg/kg/d. Maternal toxicity in the 1000 mg/kg/d group included: decreased body weight (BW loss during the premating interval, 10.9% on GD 21, 10% on lactation day 4), increased kidney (also seen in 300 mg/kg/d females) and liver weights, thymic atrophy, decreased splenic hematopoiesis, and one death. Signs of reproductive effects included low number of estrus cycles, prolonged gestation period, decreased number of corpora lutea and implantation sites, decreased parturition index, neonatal death during the lactation period and reduced number of offspring. Maternal toxicity was also observed in the 300 mg/kg/d group in the form of increased kidney weights. At 300 mg/kg/d the number of live pups born per dam was reported to be significantly decreased from 15.0 ± 1.4 in controls to 13.4 ± 1.5 (p < 0.05) in treated animals (Furuhashi et al., 1998) . However, subsequent reanalysis showed that the number of pups at this dose level was within the range of historical control data (Müllerschön, 2014; personal communication) . When analyzing the live pups in control groups of 15 studies of the same laboratory the arithmetic mean was 14.28 (standard deviation 0.08) with a minimum of 13.1 and a maximum of 15.4. This shows that the number of live pups born in the contemporary control group was in the very high range of historical control data and for only 3/15 control groups the number of pups born was > 15.0. On the other hand, the number of pups at 300 mg/kg/d was in the low historical dose range with 3/15 studies showing numbers of live pups of ≤13.4 in historical controls. In addition, the very small standard deviation of ± 1.4 or ± 1.5 for the control and exposure groups of Furuhashi et al. (1998) may have contributed to the observed statistical significance: in only 3/15 historical control groups the standard deviation was < 1.4 with a total range between 0.9 and 3.7. Hence, the finding at 300 mg/kg/d is of no biological significance and the NOAEL for effects on maternal fertility was 300 mg/kg/d (corresponding to 1.52 mMol/kg/d).
In a 90-day gavage study with 2-EHMA in rats reproductive organs were not affected (organ weights and histopathology) at the highest dose level. The overall NOAEL of the study was 120 mg/kg/d for systemic effects (defined by decreased body weights) and 360 mg/kg/d (corresponding to 1.82 mMol/kg/d) specifically for the reproductive organs (BASF, 2009a) . It is noted that the lowest NOAELs were obtained from the oral OECD 422 studies for effects in pregnant females. 4.9.1.1. Comparison of methacrylate esters with their alcohols. The data are summarized in Table 8. MMA vs. methanol: In a 2-generation study with methanol by inhalation, parameters related to fertility were not affected at the highest dose of 1.3 mg/l (1000 ppm). This leads to a systemic body burden of 39 mMol/kg/d taking into account the daily exposure duration of 20 h. A 13 week study in male rats investigated testes morphology and testosterone production only. The NOAEL was 800 ppm (the highest dose tested) corresponding to 44 mMol/kg/d based on the extended exposure schedule of 20 h/d, 7 d/week. All NOAELs for MMA and methanol stem from the highest doses tested and were by a factor of 10 higher for methanol than for MMA. Inconsistent findings reported on the ECHA (2017b) website should be mentioned: one study described indications for decreased testosterone levels, without time and dose response, after exposure of male rats to methanol (0.265, 2.65, 13.3 mg/l) over 1, 2, 4 and 6 weeks. In addition luteinizing hormone (LH) was increased at the highest dose after 6 weeks. In a later study with the same design, the effect on testosterone at 0.265 mg/l (the only dose tested here) could not be reproduced. These data are not taken into consideration here as the findings of the first study were inconsistent and the second study only retested the lowest dose.
n-BMA vs. n-butanol: In a 2-generation study with n-butanol in rats H.-P. Gelbke et al. Regulatory Toxicology and Pharmacology 92 (2018) 104-127 by inhalation, the highest dose of 2000 ppm was the NOAEL for fertility corresponding to a systemic body burden of 24.3 mMol/kg/d. A 13 week inhalation study with n-butyl acetate gave a NOAEL of 3000 ppm (the highest dose tested) by histopathology of male and female reproductive organs, corresponding to 36.4 mMol/kg/d. The use of data from n-butyl acetate to extrapolate to n-butanol has been proposed by OECD (2001) . In an oral 13 week study with n-butanol complete histopathology did not show adverse effects of the male and female sex organs up to the highest dose with a NOAEL of 500 mg/kg/d corresponding to 6.8 mMol/kg/d. Taken together these comparisons show much higher NOAELs for n-butanol as compared to n-BMA for sex organs in males and non-pregnant females as well as for pregnant females in the 2-generation study as compared to the OECD TG 422 screening protocol. It is noted that the effects observed in the OECD TG 422 screening study with n-BMA were not found in the 2-generation study with n-butanol. 2-EHMA vs. 2-ethylhexanol: A 2-generation feeding study with rats is available for bis(2-ethylhexyl)terephthalate, a chemical that is rapidly metabolized to terephthalic acid and 2-ethylhexanol similarly to many other esters. Calculated for 2-ethylhexanol the NOAEL ranged from 149 to 516 mg/kg/d for male and female parental animals of the F0 and F1 generation, corresponding to 1.15-3.97 mMol/kg/d. This was the highest dose tested. But the rate of ester cleavage for both of the alcohol moieties of this bifunctional ester is unknown. Therefore the data obtained with this chemical will not be used here. 90 day oral and inhalation studies have been performed with complete histopathology for 2-ethylhexanol. In the oral study relative testes weights were significantly increased at the highest dose (500 mg/kg/d) but this corresponded to a reduced body weight at this dose level. There was a statistically significant decrease of relative ovary weights at the mid dose of 250 mg/kg/d without a dose response relationship. Therefore, these findings on gonadal weights cannot be considered as primary adverse effects on gonads. As histopathological alterations of the reproductive organs were not observed, the NOAEL for fertility was 500 mg/kg/d, corresponding to 3.85 mMol/kg/d, the highest dose tested. In the 90 day inhalation study the NOAEL of 2-ethylhexanol for effects on the reproductive organs was 120 ppm, corresponding to 1.42 mMol/kg/d. 120 ppm was the highest dose tested and corresponded to the saturated vapor concentration. Taking into account this limitation of dose selection by vapor concentration, these data show that the NOAELs for 2-ethylhexanol are in the same range or higher as those for 2-EHMA for males and non-pregnant females. But for 2-ethylhexanol no information is available for effects on females after pregnancy that might correspond to the findings in the OECD TG 422 study. 4.9.1.2. Summary and discussion of fertility effects in studies with oral and inhalation exposure. The NOAELs derived from the different study types are summarized in Table 8 , calculated also on a mMol/kg/d basis for comparison. Taking into consideration the uncertainties associated with numerical values for NOAELs, those for MAA (90 day inhalation study) and MMA (2-generation study, oral; 13/52 weeks inhalation study) are virtually the same, i.e. between 3.9 and 4.5 mMol/kg/day both for oral and inhalation exposure. But the NOAELs for n-BMA and 2-EHMA are lower by a factor of about 2-3 based on the OECD TG 422 studies. Apart from the 2-generation study with MMA, these are the only investigations covering female reproduction during/after pregnancy. For inhalation exposure the database is limited to repeated dose studies with MAA and MMA. Therefore for this route of exposure, prediction is based on oral NOAELs taking into consideration the respiratory volume of rats.
In most investigations with methacrylic esters the NOAELs for potential effects on fertility correspond to the highest dose tested. The only exemptions are the oral OECD TG 422 studies with n-BMA and 2-EHMA with NOAELs of 2.11 and 1.52 mMol/kg/d, respectively, based on effects in pregnant females. In both of these studies, a high degree of maternal toxicity was also observed at dose levels affecting fertility. The LOAEL for n-BMA related to fertility is 7.0 mMol/kg/d defined by decreased numbers of corpora lutea and implantations. The LOAEL for 2-EHMA is 5.1 mMol/kg/d because of low number of estrus cycles, prolonged gestation period, decreased number of corpora lutea and implantation sites, decreased parturition index, and reduced number of offspring. For the corresponding alcohols the NOAELs are clearly higher and reach in most cases the highest dose tested.
The findings in the OECD TG 422 studies with n-BMA and 2-EHMA are unique in that these are (apart from an oral 2-generation study with MMA) the only methacrylate investigations with detailed analyses of females after pregnancy. For the alcohols, 2-generation studies in rats with methanol, n-butanol, i-butanol and ethanol (in mice) show high NOAELs between 24.3 and 170 mMol/kg/d. Therefore, the alcohols moieties cannot be responsible for the effects observed in the OECD TG 422 screening tests. The higher NOAEL of 4 mMol/kg/d in the 2-generation study with MMA provides good evidence that also MAA is not responsible for the effects observed after pregnancy. Therefore, most probably residual parent esters of n-BMA and 2-EHMA could be the driving moieties for the effects noted in the OECD TG 422 screening studies indicating that fertility in females may in part correspond to scenario 4 of ECHA (2015, 2017a) . This assumption is supported to a certain extent by the fact that the NOAEL of 2-EHMA is lower than that of n-BMA corresponding to the increased half-life of the intact ester with molecular weight. Due to the remaining uncertainties in this respect, a conservative read-across is used for i-BMA taking the lowest NOAELs observed with pregnant females in the OECD TG 422 screening test in pregnant females with 2-EHMA, 1.52 mMol/kg/d. As for MMA an oral guideline 2-generation study has been carried out with a NOAEL of 4 mMol/kg/d, this data point is used for EMA in preference to a readacross from the screening test with n-BMA. The close structural similarity between MMA and EMA supports this approach. Under these premises, a NOAEL for fertility of 4 mMol/kg/d, corresponding to 456 mg/kg/d (oral exposure) and 350 ppm (inhalation) is obtained for EMA. For i-BMA the NOAEL taken from 2-EHMA (1.52 mMol/kg/d) corresponds to 216 mg/kg/d and 130 ppm. The NOAELs after inhalation for n-BMA and 2-EHMA can be directly derived from the oral NOAELs with 180 ppm for n-BMA and 131 ppm for 2-EHMA. The NOAEL for 2-EHMA is well above the saturated vapor pressure.
Although the alcohol moieties are not assumed to be pivotal for defining the NOAELs for fertility, for the predicted NOAELs of EMA and i-BMA a comparison is made with information available for ethanol and i-butanol published on the ECHA (2017b) website. For ethanol a 2-generation study in mice was identified as key study. Although all other studies with methacrylate esters used rats, this investigation is taken here for comparison purpose. Based on effects noted in the F1 generation, the NOAEL was 10% in drinking water corresponding to 13,800 mg/kg/d or 300 mMol/kg/d. By allometric scaling with a factor of 4/7 based on ECHA (2012), this can be extrapolated to rats giving 170 mMol/kg/d. For i-butanol a 2-generation inhalation study is listed as key investigation. No effects on fertility and its parameters were found at the highest concentration tested, 7500 mg/m 3 (2500 ppm) corresponding to 29 mMol/kg/d. In addition, in the 90 days drinking water study mentioned above reproductive organs were not affected at the highest dose level of 1450 mg/kg/d (19.6 mMol/kg/d). These studies show that on a mMol/kg/d basis the NOAELs for ethanol and ibutanol are far above the NOAELs derived for EMA and i-BMA by extrapolation from MMA and 2-EHMA. This comparison of the available data shows that the predicted NOAELs of the methacrylate esters are lower than those of the corresponding alcohols. One uncertainty exists, namely that the NOAELs are often derived from the highest dose tested and the real NOAELs and LOAELs, if determined more precisely, would be higher. Nevertheless, the conclusion is justified that effects on fertility for the predicted NOAELs are not driven by the alcohol metabolites.
As explained above, prediction of the NOAEL for i-BMA was based on the effects observed in pregnant females in the OECD TG 422 study with 2-EHMA. On the other hand, all NOAELs for methacrylate esters in repeated dose studies (and for the oral 2-generation study with MMA) are clearly higher and correspond to the highest doses tested. Therefore, a NOAEL for i-BMA may also be derived separately for males and nonpregnant females on the basis of these repeated dose studies. The most conservative approach would be to use the NOAEL from the oral 90 day study with 2-EHMA (1.82 mMol/kg/d) leading to a predicted NOAEL for i-BMA of 259 mg/kg/d and 155 ppm for males and non-pregnant females. This certainly is a very conservative prediction as it is not only based on the lowest NOAEL in repeated dose studies, but was also the highest dose tested in that study.
According to Blackburn and Stuard (2014) the uncertainty of the read-across to EMA and i-BMA for pregnant females is low under consideration of the conservative approaches used. Also the uncertainty for read-across for males and non-pregnant females is low (cf. electronic supplement). Apart from the general considerations in section 2.6, this assessment is based on the number of studies available (following present days' guidelines). No effects were noted in the 2-generation study with MMA. For n-BMA and 2-EHMA effects on pregnant females were found in the OECD TG 422 screening study. There is some indication that these findings might be related to the intact ester. Therefore, for potential effects on pregnant females, interpolation from the lowest NOAEL of 2-EHMA was used for i-BMA, while the extrapolation for EMA was based on the NOAEL of MMA (the highest dose tested). No effects were noted on the male and female (non-pregnant) reproductive system for several of the esters. The effects on fertility were not driven by the alcohol or MAA.
Developmental toxicity
In Table 9 the observed and predicted NOAELs of the methacrylate esters for developmental toxicity in rats after inhalation and oral exposure (including rabbits) are summarized. In addition, the NOAELs of the corresponding alcohols are listed. Information on developmental toxicity can be derived from data obtained by test protocols of different levels of complexity: studies specifically designed to assess prenatal developmental toxicity, reproduction/developmental toxicity screening tests, and multi generation studies. The following studies are available for the members of the category: guideline studies for prenatal developmental toxicity for MAA, MMA, EMA, and n-BMA, reproduction/ developmental toxicity screening studies (OECD 422) for n-BMA and 2-EHMA and a guideline two-generation reproductive toxicity study for MMA.
MAA: A study according to the principles of the OECD guideline for prenatal developmental toxicity in rats (gestation day, gd 6-20) by inhalation showed maternal toxicity at 300 ppm, the highest concentration tested (decreased maternal weight gain and food consumption). This finding compares well to the LOAEL in the 90 day inhalation study of 350 ppm (BASF, 2008) where in addition histopathological alterations in the nasal passages of a few females were observed. The NOAEL for developmental toxicity was 300 ppm (corresponding to 3.3 mMol/kg/d), the highest exposure level tested (Saillenfait et al., 1999) .
MMA: In a guideline study for prenatal developmental toxicity with rats by inhalation according to the former OECD guideline (exposure gd 6-15) maternal effects (minimally and transiently reduced body weight and feed consumption) occurred at all dose levels (99-2028 ppm). The NOAEL for developmental toxicity was 2028 ppm (corresponding to 22.7 mMol/kg/d), the highest exposure level tested (Solomon et al., 1993) .
In another OECD guideline study for prenatal developmental toxicity with rabbits dosed orally maternal effects were observed at 150 and 450 mg/kg/d (reduced body weight gain of −31% and food consumption of −18% at the highest dose). The NOAEL for prenatal Table 9 Developmental toxicity in rats -summary of observed and predicted NOAELs for methacrylates and comparison with alcohols. developmental toxicity was 450 mg/kg/d (corresponding to 4.5 mMol/ kg/d), the highest dose level tested (BASF, 2010a). Allometric scaling using a factor of 4/2.4 according to ECHA (2014) could be used to derive a NOAEL for rats of 7.5 mMol/kg/d. However, the appropriateness of deriving such a value is questionable in the light of possible species differences in sensitivity of rats and rabbits for developmental toxicity. Therefore, the NOAEL in the rabbit will be taken forward without allometric scaling for the discussion below. In the oral OECD guideline 2-generation reproduction toxicity study in rats by gavage described above the NOAEL for developmental toxicity in the F1 and F2 progeny was 400 mg/kg/d (corresponding to 4.0 mMol/kg/d), the highest dose tested (BASF, 2010) .
EMA: A study according to the principles of the OECD guideline for prenatal developmental toxicity in rats by inhalation showed marked maternal toxicity at 1200-2400 ppm (reduced body weight gain and food consumption). At the highest concentration tested (2400 ppm) EMA was excessively toxic as evidenced by absolute maternal body weight loss between gd 6-21 of −7 g in comparison to +28 g in controls (measured by subtraction of gravid uterus weight from the body weight gain from GD 6-21). In the 1200 and 1800 ppm groups absolute maternal body weight gains were 46% and 14% relative to controls. Due to reduced fetal body weights starting at 1200 ppm the NOAEL for developmental toxicity was 600 ppm (corresponding to 6.8 mMol/kg/d) (Saillenfait et al., 1999) . But even at this lowest dose level, absolute maternal body weight gain was only 68% of that of the control group indicating that the reduced fetal body weights are probably a secondary effect related to maternal toxicity. n-BMA: A study according to the principles of the OECD guideline for prenatal developmental toxicity in rats by inhalation showed mild maternal toxicity at 300 ppm (transient reduction of maternal weight gain and food consumption) that was more pronounced at 600 and 1200 ppm, the highest concentrations tested. In the 300, 600 and 1200 ppm groups absolute maternal body weight gains were 93%, 78% and 70%, respectively in relation to controls. Increased incidences of skeletal variations occurred at 1200 ppm. Reduced fetal body weights starting at 600 ppm are probably a secondary effect related to maternal toxicity. No indication for developmental toxicity was found 300 ppm (corresponding to 3.45 mMol/kg/d) (Saillenfait et al., 1999) .
In another OECD guideline study for developmental toxicity with rabbits dosed orally, maternal toxicity (reduced food consumption and body weight gain) was observed at 300 and in excessive form at 1000 mg/kg/d, the highest dose level. In the 1000 mg/kg/d group, gross and absolute body weight gain was decreased by 55%, accompanied by abortions, stomach erosions, and clinical observations of no or watery feces. There was complete postimplantation loss in 2 individual does secondary to the distinct maternal toxicity. Based on reduced fetal body weights and increases in common skeletal variants at 1000 mg/kg/d, the NOAEL for embryo/fetal toxicity was 300 mg/kg/d (corresponding to 2.1 mMol/kg/d) (BASF, 2010b). But even this dose level exhibited clear maternal toxicity with a reduction of absolute body weight gain by 37%. By allometric scaling with 4/2.4 according to ECHA (2014) this dose would correspond to a NOAEL for rats of 3.5 mMol/kg/d. However, as mentioned previously, allometric scaling is questionable in the light of possible species differences of rats and rabbits in sensitivity for developmental toxicity, so again the NOAEL in the rabbit will be taken forward without allometric scaling for the discussion below.
In an oral reproduction/developmental toxicity screening study (OECD TG 422) with rats described above developmental toxicity parameters were not affected. Based on decreased body weight and food consumption at 1000 mg/kg/d in parental females, the NOAEL for maternal toxicity was 300 mg/kg/d and for developmental toxicity 1000 mg/kg/d, the highest dose tested (corresponding to 7.0 mMol/kg/ d) (Ito et al., 1998) . It is to be noted that the OECD TG 422 guideline does not allow a detailed assessment of developmental effects due to its screening character. Therefore the guideline prenatal toxicity studies clearly carry a greater weight than the OECD TG 422 study.
2-EHMA: In the OECD TG 422 screening study already described in the section on fertility, significant maternal and secondary developmental toxicity (decreased neonatal body weights and number of offspring, increased neonatal death) was observed at 1000 mg/kg/d, the highest dose tested. The authors also reported at 300 mg/kg/d a decreased number of neonates (Furuhashi et al., 1998) . But this could not be verified in a subsequent reanalysis (Müllerschön, 2014; personal communication) . Hence, the NOAEL for maternal and developmental toxicity was 300 mg/kg/d (corresponding to 1.5 mMol/kg/d).
In summary, no malformations or fetal death (apart from 2-EHMA) were observed for any of the substances tested. Apart from the OECD TG 422 screening test with 2-EHMA, signs for fetal toxicity generally were only unspecific and associated with maternal toxicity. 4.9.2.1. Comparison of methacrylate esters with their alcohols. The data are summarized in Table 9 . The interpretation of the relationship of the NOAELs for the methacrylate esters and the alcohols is partly compromised because several NOAELs stem from the highest doses tested and the real NOAELs and LOAELs cannot be precisely determined.
MMA vs. methanol: In the oral 2-generation study with MMA the NOAEL was 4.0 mMol/kg/d, the highest dose tested. This may be compared to a 2-generation OECD guideline study by inhalation (20 h/ d) with methanol with a NOAEL of 100 ppm (0.13 mg/l), corresponding to 3.9 mMol/kg/d. The NOAEL was based mainly on reduced brain weight in offspring at the next higher concentration of 1000 ppm, reflecting the very broad dose spacing. The prenatal developmental toxicity study with MMA (NOAEL, 2028 ppm, the highest dose tested, exposure during gd 6-15) may be compared to two similar investigations with methanol in rats. In one study (comparable to present guidelines; exposure during gd 1-19, 7 h/d) the NOAEL was 5000 ppm (6.65 mg/l) corresponding to 70.3 mMol/kg/d. At the next higher dose (10,000 ppm) external, soft tissue and skeletal abnormalities were observed. In the other one (exposure during gd 7-17, 22.7 h/d) the NOAEL was 1000 ppm (1.33 mg/l) corresponding to 45.6 mMol/kg/d. At the next higher concentration (5000 ppm) the number of viable pups was decreased and abnormalities were observed. For calculation of the internal doses the different daily exposure durations were taken into consideration. Overall, the internal body burdens at the NOAELs generally were higher for methanol than for MMA.
EMA vs. ethanol: In a prenatal developmental toxicity study by inhalation of EMA the NOAEL was obtained at 600 ppm, corresponding to 6.8 mMol/kg/d. In a similar investigation with ethanol (comparable to present guidelines; 7 h/d instead of 6 h/d, gd 1-19) the NOAEL was assessed as being 20,000 ppm, the highest concentration tested. At 20,000 ppm maternal toxicity with narcosis and reduced food intake was observed. The number of litters with abnormal fetuses was increased compared to controls, albeit only of borderline statistical significance. Therefore a conservative interpretation leads to a NOAEL at the next dose level of 16,000 ppm (30.4 mg/l), i.e. 224 mMol/kg/d, still much higher than that of EMA. In this context it should be recognized that ethanol is a known teratogen in humans.
n-BMA vs. n-butanol: No developmental effects were observed in rats with n-BMA in an oral OECD TG 422 screening study at 7 mMol/ kg/d (highest dose tested) and in a prenatal developmental toxicity study by inhalation at 300 ppm (3.45 mMol/kg/d). Two prenatal developmental toxicity studies in rats are available for n-butanol. By inhalation (study comparable to present guidelines; 7 h/d, gd 1-19) the NOAEL for the fetuses was 3500 ppm (10.8 mg/l; 49.4 mMol/kg/d). The next higher concentration (6000 ppm) led to reduced food uptake in the dams and to slightly decreased fetal body weights. In a drinking water study (according to the guidelines of the Japanese Ministry of Health and Welfare; gd 0-20) the NOAEL for developmental effects was 19.6 mMol/kg/d (1454 mg/kg/d). The next higher dose (5654 mg/kg/ d) led to reduced fetal body weights and increased skeletal variations and in the dams to reduced body weight gain and food intake. Thus, the NOAELs for n-butanol are clearly higher than for n-BMA.
2-EHMA vs. 2-ethylhexanol: For 2-EHMA only an OECD TG 422 screening study is available with a NOAEL of 1.5 mMol/kg/d. For 2-ethylhexanol a valid prenatal developmental toxicity study by inhalation (comparable to present guidelines; 7 h/d) with exposure from gd 1-19 led to a NOAEL for fetuses of 2.21 mMol/kg/d (850 mg/m 3 ).
Minor signs of maternal toxicity (reduced food consumption and body weight gain) were observed. Only one dose was tested at the saturated vapor concentration. Overall, the NOAEL for 2-ethylhexanol is higher than that for 2-EHMA, but the different study designs (prenatal toxicity by inhalation only at maximal vapor saturation vs. oral OECD TG 422 screening study) are noted.
4.9.2.2. Summary and discussion of developmental effects in studies with oral and inhalation exposure. The NOAELs of methacrylate esters derived from the different study types are summarized in Table 9 , calculated also on a mMol/kg/d basis for comparison. It should be noted that in many studies the NOAELs for fetal toxicity were still associated with maternal toxicity. NOAELs from guideline prenatal developmental toxicity studies are considered most reliable. In consideration of the uncertainties associated with numerical values for NOAELs, most are very similar in the range of 2.1-4.5 mMol/kg/d for prenatal toxicity studies also including that of MAA. This indicates that the hypothesis is valid assigning predominantly scenario 3 of ECHA (2015, 2017a) to this endpoint. The NOAEL for EMA is somewhat higher with 6.8 mMol/kg/d but that of MMA clearly falls out of this range (Solomon et al., 1993; 22 .7 mMol/kg/d, factor of 5-11). Whether this is due to the more limited exposure duration (only on gd 6-15) or to different depths of investigation or interpretation of fetal effects cannot be determined. Also the NOAELs for study types with more limited sensitivity for prenatal toxicity are within or close to this range:
The NOAEL for the 2-generation study with MMA is 4 mMol/kg/d and the NOAELs for the OECD TG 422 screening studies are 1.5 and 7.0 mMol/kg/d for 2-EHMA and n-BMA, respectively. Taken together, all data, apart from the inhalation study with MMA, show that the NOAELs for developmental toxicity are similar for all members of the group. For inter-and extrapolation to the other group members by inhalation exposure (the route most relevant for this group of chemicals) it is proposed to start from the NOAEL for MAA, the common metabolite, i.e. 300 ppm, 3.3 mMol/kg/d, corresponding to the very similar NOAEL for n-BMA (3.45 mMol/kg/d). The NOAEL of n-BMA (300 ppm) will be read-across to i-BMA leading also to 300 ppm. The NOAEL for MMA after inhalation exposure is clearly outside the range of the other NOAELs for unknown reasons. Therefore it may be prudent to accommodate it to the range of the other substances and it is proposed to use the NOAEL of EMA, the next higher category member, namely 600 ppm. Read-across to 2-EHMA requires extrapolation that is always associated with higher uncertainty than interpolation. A conservative approach is selected starting from the oral NOAEL for 2-EHMA in the OECD TG 422 study, i.e. 1.5 mMol/kg/d, corresponding to 130 ppm, far above its saturated vapor concentration of 64.5 ppm (cf. Table 1) .
To fill in the data gaps after oral exposure for i-BMA and EMA, the NOAEL of the rabbit prenatal developmental toxicity study for n-BMA (2.1 mMol/kg/d) is used giving NOAELs of 240 mg/kg/d for EMA and 300 mg/kg/d for i-BMA. The lower NOAEL in the rabbit for n-BMA is preferred to the one of MMA (4.5 mMol/kg/d) as the more conservative approach. For the oral prenatal toxicity of 2-EHMA only the NOAEL obtained by the OECD TG 422 screening study is available (1.5 mMol/ kg/d). In spite of screening data being less reliable than observations in a prenatal toxicity study, this NOAEL will be retained for the oral route as it is more conservative than the NOAEL after inhalation of 2-ethylhexanol (2.21 mMol/kg/d).
The predicted NOAEL of EMA after oral exposure (2.1 mMol/kg/d) is much lower than that of ethanol reported in the IUCLID data set (ECHA, 2017b) for inhalation, i.e. 16,000 ppm corresponding to 224 mMol/kg/d (see above). For i-butanol prenatal toxicity studies similar to present guidelines are reported in ECHA (2017b). Both in rats (gd 6-15) and rabbits (gd 7-19) NOAELs were obtained at 10,000 mg/m 3 by inhalation, the highest exposures tested. For the rat this corresponds to 39 mMol/kg/d. Slight maternal toxicity occurred in rabbits (transient, statistically non-significant retardation of body weight gain) but not in rats at this dose level. These studies show that for ethanol and ibutanol the NOAELs are far above of those calculated for EMA (2.1 mMol/kg/d) and i-BMA (2.1 mMol/kg/d, oral and 3.45, inhalation) and that developmental toxicity would not be driven by the alcohol moiety.
According to Blackburn and Stuard (2014) the uncertainty of the read-across to EMA and i-BMA after oral exposure is low. The uncertainties for the NOAELs by inhalation exposure are also low for i-BMA and the accommodated value for MMA (cf. electronic supplement). Apart from the general considerations in section 2.6, this assessment is based on the number of studies available in rats (oral and inhalation) and rabbits (oral) (mostly following present day guidelines). In studies in which the highest dose did not correspond to the NOAEL, the signs of developmental toxicity were rather unspecific and associated with maternal toxicity. In addition, prenatal developmental toxicity of the esters was not driven by the corresponding alcohols. A higher uncertainty (low to moderate) is assigned to the NOAEL of 2-EHMA after inhalation because extrapolation is based on the oral OECD TG 422 study. In spite of the low systemic body burden, this higher uncertainty is justified because of the screening nature of the study protocol in combination with the necessary route-to-route extrapolation.
Summary of results for the different endpoints
A category approach is proposed for the toxicological assessment of short chain methacrylate esters (MMA, EMA, n-BMA, i-BMA, 2-EHMA) to fill in data gaps by read-across. The scenarios described by ECHA (2015, 2017a) have been used to describe the mechanisms relevant for the different endpoints. The scheme proposed by Blackburn and Stuard (2014) is applied to define the level of uncertainty of each read-across (cf. electronic supplement). The focus is to satisfy information requirements of the EU REACH regulation and identify NOAELs for different toxicological endpoints after oral and inhalation exposure. Implications on classification and labelling are not discussed. MMA by virtue of it being the largest volume chemical of the category has the most comprehensive dataset covering all toxicological endpoints. This category of lower methacrylate esters takes into consideration the similar ester structure modified by increasing chain lengths of the alcohol moiety from C1 to C8 leading to a monotonic incremental change of the physico-chemical properties with molecular weight (ECETOC, 2012). All members have two functional groups, the ester group and the vinylogic double bond of the acyl moiety. They have a possible common mode of action (electrophilic reactions of the intact ester) and a common first step metabolism (ester cleavage) leading to MAA as common, secondary source chemical. The electrophilicity of methacrylate esters is not very pronounced because of the +I-effect and steric hindrance of the alpha-methyl group. A minor + I-effect is exerted by the alcohol moiety leading to a slight decrease of electrophilicity with increasing molecular weight. Ester hydrolysis is the major metabolic pathway and electrophilic reactions may only play a minor modifying role.
The assessment depends predominantly on similarities and monotonic changes in toxicokinetics and metabolism of the esters with increasing molecular weight. The members of the group are readily absorbed by all routes and rapidly hydrolyzed beginning already at the site of first contact as carboxylesterases are widely distributed throughout the body. Clearance of the parent ester from the body is rapid with an initial half-life in the order of minutes that increases with the alcohol chain length. The increase of terminal half-life with molecular weight is more pronounced, most probably in parallel with intermediary storage in fat tissue with increasing lipophilicity. As soon as the ester reaches systemic circulation, > 99% of the ester is hydrolyzed by first pass liver metabolism. The common primary metabolite, MAA, is subsequently cleared again rapidly from blood mainly in the liver by entering into the physiological valine pathway with the majority of the administered dose being exhaled as CO 2 (Jones, 2002) . The other metabolites, short-chain alkyl alcohols, are high production volume chemicals with a broad database and well characterized standard metabolic pathways.
For humans the most relevant routes of exposure are inhalation or dermal contact. Toxicity after inhalation is governed by ester cleavage in the olfactory epithelium leading to local tissue destruction by intracellular acidic MAA. This effect depends not only on metabolism but also on local deposition. It is most prominent for MMA, followed by EMA, while the butyl esters only exhibit a very low toxicity to the olfactory tissue. Under the assumption that ester cleavage and intracellular MAA drive local toxicity and taking into account nasal airflow pattern and activities of carboxylesterases, modelling showed rats are more sensitive than humans (Andersen et al., 2002) . After entering into systemic circulation all esters and MAA are rapidly cleared from the blood at the end of exposure (Jones, 2002) .
For dermal exposure, in vitro studies showed that methacrylate esters were rapidly absorbed through epidermis and more slowly through whole skin of rats. The absorption rate decreased with increasing molecular weight with complete cleavage of the parent ester during passage through whole skin in the case of n-BMA and higher esters, but not for MMA. As is the case with many chemicals, human epidermis was less permeable than that of rats (Jones, 2002) .
Taking into consideration metabolism and chemical structure of the methacrylate esters, toxicity may be driven either by -direct electrophilic reactions (e.g. genotoxicity or sensitization), corresponding to scenario 4 or 6 of ECHA (2015, 2017a) depending on the endpoint -local effects caused by high intracellular concentrations of MAA after ester cleavage within the tissue of first contact (e.g. nasal toxicity after inhalation), corresponding to scenario 3 of ECHA (2015, 2017a ). -systemic effects caused by MAA as the common secondary source chemical and the corresponding alcohol due to the rapid ester cleavage (e.g. repeated dose or reproductive toxicity), corresponding to scenario 3 of ECHA (2015, 2017a) . Systemic effects may also depend on the parent ester escaping temporarily from first pass liver metabolism. This effect may play a role at high doses overwhelming the metabolic capacities of the carboxylesterases, inhalation exposure with a fraction bypassing the liver, or for higher molecular weight esters with longer terminal half-lives due to intermediary deposition in fat tissue. This corresponds to scenario 4 of ECHA (2015, 2017a) .
This category approach is based on the hypothesis that local toxicity of methacrylate esters is primarily determined by ester hydrolysis, while systemic effects are governed by MAA as a common metabolite of all members possibly in combination with the intact ester in the case of the higher members, while the different alcohols due to their low toxicity do not play a decisive role. The category approach was applied to the different toxicological endpoints and the following results were obtained:
Data for all members of the category are available for acute oral toxicity, skin and eye irritation and skin sensitization and read-across was not necessary. For these endpoints low to moderate toxicities were observed. Read-across for genotoxicity was not carried out as this is available from a recent review of Albertini (2017) that concluded a low concern for genotoxicity in-vivo. Read-across showed a low acute dermal toxicity when extrapolated to EMA, i-BMA and 2-EHMA. For 2-EHMA the LC 50 was predicted to be above the saturated vapor concentration but a numerical value could not be assigned with sufficient certainty.
The NOAELs for repeated dose studies available and predicted by read-across are summarized in Table 10 . While in the former tables ranges were given for the extrapolated subchronic/chronic NOAELs, in Table 10 only the lowest, most conservative values are listed. This conservatism adds to the level of confidence when eventually using these NOAELs for risk assessment purposes. NOAELs for local and systemic effects were derived separately as were those for oral and inhalation exposure. While local effects depend on the concentration impacting on the tissue of first contact, systemic effects are driven predominantly by the products of rapid ester hydrolysis, i.e. MAA and 
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Levels of confidence (ECHA, 2015 (ECHA, , 2017a and uncertainty (Blackburn and Stuard, 2014 H.-P. Gelbke et al. Regulatory Toxicology and Pharmacology 92 (2018) 104-127 the alcohols. Therefore for systemic effects, doses should be compared on a molar basis, leading to comparable internal amounts of the metabolites. Repeated dose toxicity: Systemic effects in repeated dose studies up to 2 years after oral or inhalation exposure generally were confined to nonspecific toxicity, such as decreased body weights or slight effects on liver or kidney. For oral exposure the NOAELs converged to a range of 0.5-1.5 mMol/kg/d for MMA, n-BMA and 2-EHMA and for ready-across the most conservative NOAEL of 0.5 mMol/kg/d was used. Thereby a NOAEL of 57 mg/kg/d was obtained for EMA and of 68 mg/kg/d for i-BMA. Signs of local (i.e. gastro-intestinal tract) irritation were not noted in any of the oral studies. This principal approach is supported by the fact that also after inhalation exposure the systemic NOAELs were in the same range with ∼1 mMol/kg/d for MAA and MMA. An exception was a very high experimental NOAEL in a 28 day study with n-BMA of 11 mMol/kg/d. As this was inconsistent and unexplainable, a value of 1 mMol/kg/d is also used for exposure durations of 90 days and above for n-BMA. The systemic NOAEL of 1 mMol/kg/d for inter-and extrapolation led to 90 ppm for EMA, i-BMA and 2-EHMA for systemic effects after inhalation.
For local effects after inhalation, the NOAEL of MMA of 25 ppm obtained in the 2 year study of Lomax et al. (1997) may be directly extrapolated to EMA in a conservative manner, as EMA led to a less pronounced olfactory degeneration in comparison to MMA after acute exposure (Jones, 2002) . The local NOAEL of n-BMA of 310 ppm was obtained in a 28 day inhalation study. Local effects after inhalation of methacrylate esters will at most only slightly increase with prolongation of exposure when comparing the data of Lomax et al. (1997) with a NOAEL of 25 ppm after 2 years and Hext et al. (2001) with a LOAEL of 110 ppm in the course of a 28 day study that normalized within the 28 day exposure period. Therefore a factor of 2 is considered sufficiently conservative for time extrapolation and the local chronic NOAEL for n-BMA can be defined at 150 ppm. The difference between the chronic local NOAEL for MMA (25 ppm) and the extrapolated one for n-BMA is consistent with the acute data of Jones (2002) showing at 200 ppm clear olfactory lesions with MMA but not with the butyl esters. The chronic local NOAEL for n-BMA (150 ppm) is directly taken for i-BMA and 2-EHMA. For 2-EHMA this NOAEL would clearly be above the saturated vapor concentration. When comparing systemic and local NOAELs after inhalation, for MMA and EMA the observed and predicted local NOAELs are lower than the systemic NOAELs, while the inverse is found for n-BMA, i-BMA and 2-EHMA. This is explained by the rapidly decreasing cytotoxicity to the olfactory epithelium with increasing molecular weight.
Reproductive toxicity is defined by the same principles as systemic repeated dose toxicity, namely predominantly by the products of ester cleavage. Again, quantitative comparisons between the members should preferably use a mMol/kg/d basis.
Fertility: Data from subchronic studies with detailed investigations of reproductive organs and the OECD TG 422 screening studies indicate no or low toxicity with respect to fertility. The NOAELs for fertility related effects are nearly identical for MAA and MMA (between 3.9 and 4.5 mMol/kg/d) and those for n-BMA and 2-EHMA are by a factor of about 2 somewhat lower. But with all the uncertainties surrounding numerical values of NOAELs it is unclear whether this difference has any toxicological significance. As regards the other members, the NOAEL of 2-EHMA may directly be used for i-BMA (both with a branched alcohol moiety) and that of MMA for EMA. This would lead to the following NOAELs in mg/kg/d for oral exposure: MMA 400, EMA 456, n-BMA 300, i-BMA 216, 2-EHMA 300. By route-to-route extrapolation the NOAELs for inhalation exposure would be for MMA 400, EMA 350, n-BMA 180, i-BMA 130, and 2-EHMA 130 ppm. Some indication was obtained that fertility in females might depend to a certain extent on the unmetabolized methacrylate esters, but this does not invalidate the read-across approach taking into consideration similarity of chemical structure and reactivity/electrophilicity.
Developmental toxicity: Guideline and screening studies in rats by the oral and/or inhalation route and in rabbits by oral exposure indicate no or a low potency for developmental toxicity. The NOAELs are grouped around a range of 2.1-4.5 mMol/kg/d with a marked exception for MMA after inhalation with 22.7 mMol/kg/d for unknown reasons (Solomon et al., 1993) . Read-across for the inhalation route starts from the NOAELs of MAA, the common metabolite, or n-BMA (3.3 or 3.45 mMol/kg/d). This would lead to a NOAEL of about 300 ppm for i-BMA. As the very high NOAEL of MMA clearly falls out of the range of all the other ones (oral and inhalation), a conservative approach is proposed, namely to extrapolate this NOAEL from that of EMA, i.e. 600 ppm. For 2-EHMA the inhalation NOAEL is derived from that of its oral OECD TG 422 study leading to 130 ppm. For oral exposure, the rabbit prenatal NOAEL for n-BMA (being lower than the NOAELs of MMA) is used to read-across to EMA (NOAEL 240 mg/kg/d) and i-BMA (300 mg/kg/d).
Systemic NOAELs for all repeated endpoints, either derived by readacross or actually observed, were always lower for the methacrylate esters than those of the corresponding alcohols when compared on a molar basis. Therefore the toxicological profile is not governed by the alcohols.
Carcinogenicity: A carcinogenic response may in theory be elicited by direct genotoxicity of the intact esters before metabolic cleavage. However, as the methacrylate esters do not exhibit genotoxic effects, such a mechanism is highly unlikely for all group members. After ester hydrolysis, MAA will exert cytotoxicity at the portal of entry and enter systemic circulation. MAA being not genotoxic or electrophilic will not lead to a systemic carcinogenic effect. High local intracellular concentrations of MAA may induce severe local cytotoxicity that could in principle result in a neoplastic response by a non-genotoxic mechanism. Such a pathway, if operative at all, would be most pronounced for MMA, the ester with the most prominent local ester cleavage. But MMA did not lead to a carcinogenic response after inhalation in rats, mice and hamsters and such a mechanism is therefore not to be expected for the other group members with even lower local cytotoxicity. This lack of a carcinogenic effect is supported by the non-carcinogenicity of alcohols formed by metabolic cleavage. In addition, for potential carcinogenicity studies, MTDs were derived for the other methacrylate esters to construct theoretical long-term studies. A comparison with the carcinogenicity data for the alcohols (when available) showed that a carcinogenic response is not to be expected up to the extrapolated MTDs for inhalation of EMA and oral exposure of 2-EHMA.
The category approach presented here for lower methacrylate esters was based on similarities of chemical structure, chemical and biological reactivity, metabolism and common metabolic products. A specific feature of this chemistry is the pronounced local toxicity to the olfactory epithelium after inhalation by intracellular ester cleavage to MAA, clearly decreasing with molecular weight. For systemic effects quantitative dose comparisons were based on equimolar body burdens. A very similar toxicological profile was observed for all members, sometimes with a clear trend following molecular weight. Data gaps could be filled in by read-across generally with high confidence. Thereby it was found for prolonged exposure that the chemicals of this category exhibit low systemic toxicity, are devoid of specific reproductive effects and a carcinogenic response is not to be expected. Local toxicity after repeated inhalation decreases with increasing molecular weight.
Discussion and conclusion
With the extensive use of read-across in dossier submissions under REACH and the release of the March 2017 version of ECHA's RAAF on categories and read-across, is seemed timely to test the practical applicability of this guidance to this relatively straight forward category. A category approach for this group was first submitted in 2010 under REACH. This category appears to meet all the requirements set out in ECHA's pre-conditions, namely well-defined and unambiguous identity of the donor and target chemicals. A strong feature of this category was the good understanding of methacrylate chemistry and Michael reactivity combined with extensive studies of the biological fate/toxicity of the chemicals so this provided a firm basis for the category justification. The upper boundary (2-ethylhexyl ester) was defined based on practical exposure considerations and physico-chemical properties beyond which the structure related trends broke down. The scenarios underpinning the RAAF guidance were carefully selected and applied to determine the relevant assessment elements against which the strengths of the read-across results could be measured. Using the uncertainty analysis of Blackburn and Stuard (2014) the level of uncertainty was low for most endpoints for which read across was employed. Since the process of applying the RAAF guidance even to this relatively straight forward category was quite challenging, it is envisaged that in other cases with less profound understanding of these aspects the process of category definition would be more haphazard and open to challenge.
Assessment of the level of confidence (or uncertainty) in the use of read-across to fill data gaps is essential for its scientific and regulatory acceptability. In this respect ECHA (2015, 2017a) defines 5 levels of confidence as assessment options for regulators when reviewing a readacross submitted under REACH. While these levels align well with the REACH regulatory process they do lack detailed definition. In contrast, the approach described by Blackburn and Stuard (2014) set out very clearly the most important criteria for defining uncertainty. Both systems are very similar (see Table 11 ), although the Blackburn and Stuard (2014) process uses the term "uncertainty" as opposed to "confidence" and has 4 levels rather than 5. We chose to use the system described by Blackburn and Stuard (2014) to score all endpoints, i.e. the number of contributing data, robustness of the data set, concordance of effects, concordance of potency, and severity of critical effect (cf. electronic supplement) since it was more transparent and could be applied consistently across the case study. It is envisaged that this could be an aspect of the RAAF guidance that could be strengthened in due course.
There are 2 overarching hypotheses or AOPs for this category that determine how the read-across process is constructed and most importantly ensured that the most appropriate scenarios and assessment elements are selected. In this case both OAPs are associated with low uncertainty:
-Electrophilicity of the intact ester. This may in principle lead to local or systemic effects. For this group electrophilicity is low and decreases only slightly with molecular weight for all group members and therefore will only have a minor impact over the group, apart possibly from sensitization and genotoxicity. -Ester cleavage to MAA and the corresponding alcohol. For this AOP the impacts of the products of ester cleavage (MAA and the corresponding alcohol) are different for systemic and local effects. Both hydrolysis products can be assumed to have only low systemic toxicity because MAA is rapidly metabolized by physiological pathways and for the corresponding alcohols the NOAELs were always found to be higher than those of the source and extrapolated data. A different situation exists for local effects, especially after inhalation. Here local toxicity is driven by intracellular production of MAA leading to cytotoxicity by decreased pH and a broad database is available for this pathway enabling a read-across over the total category.
The more specific elements for uncertainty analysis according to Blackburn and Stuard (2014) are presented in the electronic supplement and show that the uncertainties are generally low for all endpoints analyzed. This is especially important for repeated dose toxicity after oral and inhalation exposure since these are key endpoints from both data requirement and animal protection perspectives.
It should be recognized that a robust read-across approach is only as good as the data on the donor chemistry. In this regard we were very fortunate since in general, -the number of donor substances contributing data was sufficient for both exposure routes -the vast majority of available studies followed present days' guidelines -effects noted at the LOAELs were unspecific and not life threatening (and for fertility and developmental effects often associated with maternal toxicity) -the NOAELs were in similar ranges (also including MAA as secondary source chemical) -NOAELs of alcohols (the other metabolic cleavage products) were always higher than the source and extrapolated NOAELs -finally, whenever several options existed for extra-or interpolation, the most conservative option was selected.
There are two exceptions with what were considered to be of higher uncertainty:
-For acute inhalation toxicity (LC 50 ) of 2-EHMA, the uncertainty is low that mortality will not occur at concentrations below the saturated vapor concentration, but high for any extrapolation into concentrations that are likely associated with aerosol generation. -The uncertainty for the NOAEL for developmental toxicity of 2-EHMA after inhalation was low to moderate because it was based on the NOAEL of its oral TG 422 screening study. This higher uncertainty is justified because of the screening nature of the study protocol in combination with the necessary route-to-route extrapolation. But it is noted that the extrapolated NOAEL of 130 ppm is clearly higher than the saturated vapor concentration of 64.5 ppm.
We were able to confirm that the framework proposed by ECHA in its RAAF guidance (ECHA, 2015 (ECHA, , 2017a can be used to fill data gaps for a wide variety of human health endpoints both qualitatively and quantitatively for the chemistry under consideration here. It is very evident, however, that establishing a hypothesized mode of action (MOA)/adverse outcome pathway (AOP) for each endpoint is as essential as it is having robust toxicological data against which the readacross is being proposed. For chemical domains for which the MOA/ AOP is well established or can be anticipated with high confidence this type of approach is a valuable tool and its use should be encouraged in the future as it has the potential to significantly reduce the need for further testing. One aspect that became very evident in this exercise and that is being borne out by practical experience with other registrations under REACH is that read-across hypotheses that depend on metabolism as a key step in the MOA/AOP are practically challenging not only from the perspective of having to develop half-life data linking the target (parent) to the donor chemical, but also from the necessity to demonstrate very short half-lives together with robust data on the toxicities of the main metabolites. This requirement for a high burden of proof could potentially render the widespread use of read-across unachievable. Regulators and industry will need to place realistic expectations in this regard if categories and read-across are to achieve the cost and animal savings that are promised.
It has to be recognized that the concept of read-across and the many different ways in which it can be used poses a significant challenge for industry and regulators alike since unless they can develop a common language it is unlikely that they will ever gain sufficient confidence in it to fully replace toxicity testing. Perhaps the current experience with registrations under REACH that employ read-across and the high burden of proof that is being demanded provides testimony to this point. In this regard the RAAF makes a significant contribution in that it introduces a structured approach and common language within which the basis for the read-across and key assessment elements (AEs) can be articulated. However, ECHA recognises that the basis for the readacross may vary between endpoints and upon data availability, so there is an expectation that the most appropriate scenario, with its associated AEs, is identified and addressed for each and every endpoint. While scientifically justified this requirement introduces some real challenges in terms of switching back and forth between scenarios when going through an assessment using the traditional sequence. From our experience with this category there is no simple answer although some advantage can be gained by grouping endpoints by MOA since they often share the same scenario.
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